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1. Introduction 
Mammalian embryonic development is a complex stepwise process. Upon cleavage and 
compaction, the embryo organizes itself into the inner cell mass (ICM) and the trophoblast 
cells. At this stage, the first ICM commitment occurs. The segregation of cells within the 
ICM give rise to the epiblast (EPI) and the primitive endoderm. Cells generating the EPI 
can differentiate into the three germ layers and its associated extraembryonic tissues, thus 
are pluripotent stem cells (PSCs). Following segregation, the embryo implants into the 
uterine epithelium, initiating significant changes in (PSCs) identity and embryo morphology 
(Bedzhov et al., 2014). Embryonic stem cells (ESCs) are PSCs derived from pre-
implantation embryos at E3.5-E4.5 (Evans and Kaufman, 1981). EPI-like cells (EpiLCs), 
which differentiate from ESCs in culture, are PSCs which resemble the embryo post-
implantation stage at E5.5 (Hayashi et al., 2011). ESCs and EpiLCs reflect two distinct 
pluripotent states known as the naïve state and the primed state (formative) (Smith, 2017), 
respectively, providing a useful model system to examine the pluripotent state transition 




Fig. 1. Mouse embryonic development in vitro vs in vitro. 
ESCs are naïve PSCs derived from pre-implantation embryos, whereas EpiLCs, which can 




 - 3 - 
To date, several signaling pathways involved in pluripotency regulation have been 
identified. Leukemia inhibitory factor (LIF) and bone morphogenic factor (BMP) signaling 
are strongly involved in the maintenance of ESC pluripotency via the LIF receptor (Lifr) 
and BMP receptor (Bmpr) families, respectively (Niwa et al., 2009; Ying et al., 2003). In 
contrast, fibroblast growth factor (FGF) signaling triggers ESC differentiation into EpiLCs 
via the FGF receptor (Fgfr) family (Lanner and Rossant, 2010). Wingless-type (Wnt) 
signaling maintains the pluripotent state while at the same time priming cells for 
differentiation via interaction of Wnt ligands with Frizzled (Fzd) receptor family (ten Berge 
et al., 2011). Indeed, induction of Wnt signaling by CHIR99021 (CHIR) together with the 
FGF signaling inhibitor PD0325901 (PD) is commonly used to culture ESCs in a ground 
state of pluripotency. However, CHIR alone induces ESC differentiation (Ying et al., 2008) 
(Fig. 2). PSCs represent a promising tool to dissect the mechanisms underpinning 
mammalian development and advance regenerative medicine. Nevertheless, a significant 





Fig. 2. Signaling pathways involved in PSC pluripotency network. 
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Glycosylation is one of the most abundant post-translational modification which is 
predicted to be present on more than half of all mammalian proteins (Apweiler et al., 1999) 
and is exerted by over 200 distinct glycosyltransferases and related enzymes in mammals. 
Characterization of glycomic profile has been performed in mouse and conventional 
human ESCs (hESCs), human induced pluripotent stem cells (hiPSCs), tumors and late 
differentiating cells (Nairn et al., 2012; Fujitani et al., 2013; Homan et al., 2019). 
Nonetheless, the glycosylation dynamics during pluripotency state transition remain 
unexplored. Glycosylation is involved in a wide range of cellular processes, such as 
adhesion, signaling regulation, and endocytosis (Varki, 2017). To date, numerous studies 
have reported the critical role of glycosylation in development and stem cell regulation 
across different species (Haltiwanger and Lowe, 2004; Nishihara, 2018). However, the 
molecular mechanisms and its relationship with signaling in ESCs remains poorly 
understood. Mucin-type O-glycosylation is an evolutionarily conserved protein modification 
and is one of the most abundant forms of glycosylation present on membrane proteins and 
secreted proteins (Tran and Ten Hagen, 2013). Mucin-type O-glycosylation is 
characterized by the initial addition of N-acetylgalactosamine (GalNAc) to a serine or 
threonine residues of the target protein by a family of 19 polypeptide α-N-
acetylgalactosaminyltransferases (Galnts) in mouse; the attachment of GalNAc forms the 
so-called Tn antigen. Galactose (Gal), sialic acid (Neu5Ac), or N-acetylglucosamine 
(GlcNAc) can be successively added to Tn antigen by C1galt1, St6galnac1, and B3gnt6, to 
form three main structures: T antigen (Galβ1-3GalNAc), sialyl Tn antigen (NeuAcα2-
6GalNAc), and Core 3 structure (GlcNAcβ1-3GalNAc) (Bennet et al., 2012). The 
importance of this mucin-type O-glycosylation during embryonic development is 
highlighted by the fact that knockout of the C1galt1 gene is embryonic lethal in mice (Xia et 
al, 2004). Moreover, a novel culture comprising the primitive growth factor NME7AB, which 
binds to the extracellular domain of the cleaved form of the mucin-type O-glycosylated 
protein MUC1, was observed to maintain hESCs in an undifferentiated state (Carter et al., 
2016), indicating that mucin-type O-glycosylation plays a key role in ESC pluripotency 
network. In the present study I characterized the glycomic dynamics during mouse 
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2. Materials and Methods 
2-1. Cell culture 
R1 (Nagy et al, 1993) and E14TG2a (Smith and Hooper, 1987) ESC lines were maintained 
on mouse embryonic fibroblasts (MEF) that were prepared from embryos at embryonic day 
14.5 and inactivated with 10 μg mitomycin C (Sigma-Aldrich) at 37°C, 5% CO2. ESCs were 
maintained in ESC medium consisting of DMEM (Gibco) supplemented with 15% fetal 
bovine serum (FBS) (Nichirei Biosciences), 1% penicillin/streptomycin (Gibco), 0.1 mM 2-
mercaptoethanol (Gibco), 0.1 mM non-essential amino acids (Gibco) and 1000 U/mL LIF 
(Chemicon International). R1 ESC line was used for the experiments unless stated 
otherwise. R1 ESCs were tested for mycoplasma contamination and authenticated by 
ATCC cell line authentication service – mouse STR profiling. 
To analyze the effect of PRC2 inhibition on ESCs’ glycome, ESCs were treated with 
10 μM EED226 in ESC medium containing LIF for 48h. 
For alkaline phosphatase assay, 3-5 x 104 cells were plated on gelatin-coated 60-
mm dishes in ESC medium containing LIF. The cells were fixed and stained for ALP with 
5-bromo-4-chloro-3-indolyl phosphate-nitroblue tetrazolium (Nacalai Tesque) 4 days after 
replating. The colonies were counted by microscopy and scored manually. 
To analyze the effect of O-glycosylation inhibition, ESCs were treated with 2 mM 
GalNAc-Bn in ESC medium containing LIF for 48h. 
For galectin dissociation, ESCs were cultured in ESC medium (- FBS) containing 50 
mM lactose monohydrate (Kanto Chemical) for 30 minutes. For galectin-3 addition, ESCs 
were cultured in ESC medium (- FBS) for 2 hours before addition of 15 μg/mL Lgals3 for 
30 minutes in ESC medium (- FBS). 
 
2-2. ESCs differentiation 
EpiLC differentiation was performed following a previously established protocol (Hayashi 
et al., 2011) with slight modifications. ESCs maintained on MEF feeder cells were 
passaged on gelatin-coated 60-mm dishes (TrueLine), and cultured for 30 min in ESC 
medium containing LIF to completely remove MEF feeder cells 24h prior induction. Next, 
ESCs were seeded at low density in gelatin-coated 60-mm dishes containing ESC medium 
in the presence of 1 μM PD0325901 (Wako), 3 μM CHIR99021 (Wako) and LIF. The 
following day, EpiLC induction was performed: ESC were cultured at 1 x 106 in gelatin-
coated 60-mm dishes containing ESC medium without LIF for 24h. Subsequently, EpiLC 
medium, consisting of DMEM/F12 (Gibco) supplemented with 20% knockout serum 
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replacement (KSR) (Gibco), 2 mM L-glutamine (Invitrogen), 1% penicillin/streptomycin 
(Gibco), 0.1 mM 2-mercaptoethanol (Gibco), 0.1 mM nonessential amino acids (Gibco), 30 
ng/ml FGF2 (Wako) and 0.6 μM JAK inhibitor (JAKi) (Santa Cruz Biotechnology), was 
added. EpiLCs were collected for further analysis 72h post-induction. 
To induce embryoid body (EB) formation, ESCs were seeded in 35-mm Low Cell 
Binding dishes (Nunc) and cultured in ESC medium without LIF for 2.5, 4, 8, or 12 days. 
EB assay from transient C1galt1 KD ESCs was performed 2 days post transfection and 
collected at day 0 (ESCs), 2, 3, and 4.  
 
2-3. Vectors construct and transfection 
For knockdown (KD) of the C1galt1 in ESCs, I generated small hairpin RNA (shRNA) 
expression vectors targeting two different regions (and also enhanced green fluorescent 
protein (Egfp) as control) by inserting the double-stranded DNA between the BamH1 and 
HindIII sites of pSilencer 3.1-H1 (Ambion) or p.SUPER.retro.puro (OligoEngine), for 
transient and stable KD, respectively. shRNA sequences were designed as described 
previously (Sasaki et al., 2009) by using siDirect: 
Egfp (5’ – 3’): 
GATCCCGCCACAACGTCTATATCATGGGGAAAATCCATGATATAGACGTTGTGGCTTTTTTGGAAA 
C1galt1 KD 1 (5’ – 3’): 
GATCCCGGGCCCAGCGTTGTAATAAAGGCTTCCTGTCACCTTTATTACAACGCTGGGCCCTTTTTTA 
C1galt1 KD 2 (5’ – 3’): 
GATCCCGGCTTCTATCAAAGTATAACCGCTTCCTGTCACGGTTATACTTTGATAGAAGCCTTTTTTA 
For transient KD ESCs were plated prior to transfection in gelatin-coated feeder-free 
culture dishes in ESC medium with LIF. The next day, the cells were transfected with 2 or 
4 μg of expression vector using Lipofectamine 2000 (Invitrogen). From one day after 
transfection, the cells were selected with 2 μg/mL puromycin (Sigma-Aldrich). C1galt1 KD 
1, and C1galt1 KD 2 transfected cells were cultured for 4 days post transfection. For stable 
C1galt1 KD, p.SUPER.retro.puro vector containing C1galt1 shRNA were transfected into 
ecotropic virus-packaging (PLAT-E) cells. Supernatants containing retrovirus were 
collected 48 hours following PLAT-E transfection, mixed with 8 μg/mL polybrene (Sigma-
Aldrich), and incubated with ESCs for 24 hours. The following day, ESCs were replated 
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2-4. Real-time PCR and RNA-seq  
Total RNA was extracted from cells using TRIzol reagent (Invitrogen) and reverse-
transcribed using a Superscript II First Strand Synthesis Kit (Invitrogen) and oligo-dT 
primers. Real-time PCR was performed with an ABI PRISM 7700 Sequence Detection 
System (Applied Biosystems) and SYBR Green Master Mix (Roche). The relative amount 
of each mRNA was normalized against the amount of β-actin or Gapdh mRNA. The primer 
sets used are listed in Table 1. 
Copy number was calculated as previously described (Whelan et al, 2003). In brief, 
a region of 80-1000 bp of the St6galnac1, C1galt1, B3gnt6, and Gapdh genes was 
inserted into a pGEM®-T easy vector (Promega). The vectors were linearized and a 
concentration ranging 100-0.01 pg/μL diluted in 1 μg/mL yeast tRNA was obtained by 
serial dilution to create a standard curve for each gene. 
The RNA-seq libraries were prepared from total RNA using the TruSeq Stranded 
mRNA Prep kit (Illumina). 100 bp single-read sequencing was performed by NovaSeq6000 
(Illumina).  
 
2-5. Fluorescence-activated cell sorting (FACS) 
A single cell suspension for cell surface molecules staining was obtained using 0.02% 
EDTA/PBS. Subsequently, 2–3 x 105 cells were harvested and washed in FACS buffer 
(0.5% BSA (Iwai), 0.1% sodium azide (Sigma-Aldrich) in PBS). After washing, the cell 
suspension was incubated with Abs or lectins in FACS buffer. For internal molecules 
analysis, cells were collected with 0.25% trypsin/EDTA (Thermo Fisher Scientific) and 
fixed/permeabilized for 30 min with 100% methanol (Wako) before staining. Samples were 
then analyzed using a BD FACSAria III Cell Sorter (Becton Dickinson). Cells were gated to 
exclude debris, dead cells (identified by propidium iodide staining; Sigma-Aldrich), and 
doublets. The primary and secondary Abs and lectins used are listed in Table 2. 
 
2-6. Glycome analysis 
Cultured ESCs and EpiLCs (> 1 × 106 cells) were washed 5 times with phosphate buffered 
saline (PBS) and collected using a scraper. Collected cells were resuspended in 100 mL of 
PBS and homogenized using an Ultrasonic Homogenizer (TAITEC). Ethanol (400 μL) was 
added to the lysate and then placed at -30°C. After ethanol precipitation, the proteinous 
pellet and supernatant fractions were separated by centrifugation, then the resulting pellet 
was dissolved in 100 μL of H2O and their cellular protein concentration was measured 
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using a BCA protein assay kit (Thermo Fisher). The pellet fractions corresponding to 25 
μg, 50 μg, and 100 μg proteins were used to N-glycans, O-glycans, and GAG analyses, 
respectively. The supernatant fraction corresponding to 100 μg proteins was concentrated 
for GSL and FOS analyses. Glycomic analyses of N-glycans, GSL, and FOS were 
performed by glycoblotting methods combined with SALSA procedure (Furukawa et al., 
2008; Hanamatsu et al., 2018). O-glycome analysis was performed by BEP method and 
GAGs were measured by HPLC as previously described (Fujitani et al., 2013). 
 
2-7. Immunostaining 
Cells were fixed with 4% paraformaldehyde in PBS (PFA/PBS) and washed in PBS. The 
fixed cells were blocked with 10% Block Ace (Dainihon Pharmaceutical) in PBS (Block 
Ace/PBS), 10% Block Ace/PBS or 1%BSA/PBS with 0.3% Triton X-100 (Sigma-Aldrich) for 
the analysis of cell surface or intracellular molecules, respectively. For primary labeling, 
the cells were incubated with anti-Oct3/4 Ab (Santa Cruz Biotechnology; sc-5279; 1:100), 
anti-Nanog Ab (ReproCELL; RCAB001P; 1:100), anti-Otx2 Ab (Millipore; AB9566; 1:100), 
PNA-biotin (Cosmo Bio; J214; 1:100), anti-Fzd5 Ab (Sigma-Aldrich; SAB4503132; 1:100), 
anti-β-catenin Ab (Cell Signaling; #9562; 1:100), anti-Rab5 Ab (Cell Signaling; #46449; 
1:100), or anti-Lgals3 Ab (Santa Cruz Biotechnology; sc-32790; 1:100). Subsequently, the 
cells were stained with Alexa Fluor 555-conjugated streptavidin (Life Technologies; 
S32355; 1:300), goat anti-rabbit IgG Alexa Fluor 488-conjugated (Life Technologies; A-
11008; 1:300), goat anti-mouse IgG Cy5-conjugated (Life Technologies; A-10524; 1:300), 
anti-mouse IgG Alexa Fluor 488-conjugated (Life Technologies; A-11001; 1:300) and 
Hoechst 33342 (Invitrogen; H3570; 5 μg/mL). Images were obtained using an LSM 700 
confocal laser microscope (Carl Zeiss). Puncta staining and nuclear/cytoplasmic ratio was 
quantified using Fiji (ImageJ) software. 3D reconstructions were created using Imaris 
version 9.3.1 (https://imaris.oxinst.com). 
 
2-8. Western and lectin blotting 
Cells were lysed with lysis buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1% Triton X-
100, 5 mM EDTA, 1 mM Na3VO4, 10 mM NaF and protease inhibitors). Protein samples 
were separated on an SDS polyacrylamide gel and transferred onto polyvinylidene fluoride 
membranes (Millipore). For western blotting, membranes were blocked using 1% BSA and 
incubated with the following primary antibodies: anti-Sox2 Ab (R&D Systems; MAB2018; 
1:1000), anti-Oct3/4 Ab (Santa Cruz Biotechnology; sc-5279; 1:1000), anti-β-actin Ab 
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(Sigma-Aldrich; A5441; 1:10000), anti-p-β-catenin Ab (Cell Signaling; #9561; 1:1000), anti-
β-catenin Ab (Cell Signaling; #9562; 1:1000), anti-Fzd5 Ab (Sigma-Aldrich; SAB4503134; 
1:1000), anti-ERK1/2 Ab (Cell Signaling; #9102L; 1:1000), anti-p-ERK1/2 Ab (Cell 
Signaling; #9101L; 1:1000), anti-Akt Ab (BD Biosciences; 610836; 1:1000), anti-p-Akt Ab 
(Cell Signaling; #9275; 1:1000), anti-LRP5 Ab (Cell Signaling; #5731; 1:500), anti-LRP6 
Ab (Cell Signaling; #3395; 1:1000), anti-Nanog Ab (ReproCELL; RCAB001P; 1:1000), anti-
Otx2 Ab (Millipore; AB9566; 1:1000), anti-H3 Ab (Cell Signaling; #9715; 1:1000), anti-
H3K27me3 Ab (Cell Signaling; #9733; 1:1000), or anti-Gapdh Ab (Santa Cruz 
Biotechnology; sc-32233; 1:1000). The membranes were then incubated with anti-rabbit 
IgG (Cell Signaling; #7074; 1:10000), anti-rabbit IgG light chain specific (Jackson 
Immunoresearch; 211-032-171; 1:10000), or anti-mouse IgG (Cell Signaling; #7076; 
1:10000) HRP-conjugated secondary Ab. For lectin analysis, membranes were probed 
with PNA conjugated to horseradish peroxidase (HRP) (Cosmo Bio; J414; 1:10000). 
Membranes were then washed and developed with ECL Plus reagents (GE Healthcare). 
 
2-9. Luciferase assay 
A shRNA expression vector targeting C1galt1 (2 μg) was co-transfected using 
Lipofectamine 2000 with the reporter plasmid TOPFLASH (Upstate Biotechnology; 2 μg) or 
FOPFLASH (Upstate Biotechnology; 2 μg); pCH110 (GE Healthcare; 0.2 μg) was used as 
a control for transfection efficiency. Luciferase activity was measured 4 days after 
transfection by Dual-Light System (Applied Biosystems). Luminescence was measured 
with a Lumat LB9501 luminometer (Berthold). 
 
2-10. Immunoprecipitation and pull-down assay 
Cells were lysed with lysis buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1% Triton X-
100, 5 mM EDTA, 1 mM Na3VO4, 10 mM NaF, and protease inhibitors). A 100–500 μg of 
proteins was diluted 10-fold with wash buffer (lysis buffer w/o Triton X-100). For 
immunoprecipitation, anti-Fzd5 Ab (Sigma-Aldrich; SAB4503134; 1 μg), anti-LRP5 Ab (Cell 
Signaling; #5731; 1 μg), anti-LRP6 Ab (Cell Signaling; #3395; 1 μg), or normal rabbit IgG 
(R&D Systems; AB-105-C; 1 μg) was added. Protein G Magnetic Beads (New England 
Biolabs) were then added. For the pull-down assay, the diluted cell lysate was incubated 
with PNA-biotin (Cosmo Bio; J214; 20 μg); streptavidin magnetic beads (Bio-Rad) were 
then added. Surface biotinylation assay was performed using the Pierce cell surface 
protein isolation kit (Thermo Scientific) following the manufacturer's instruction. 
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2-11. Immunoelectron microscopy 
ESCs (5 x105) were plated on gelatin-coated 35-mm plastic dishes in ESC medium 
containing LIF. At 4 days after transfection, cells were fixed with 4% PFA/0.01% 
glutaraldehyde/PBS for 1 hour at room temperature and washed in PBS. The fixed cells 
were permeabilized with 0.5% saponin in PBS for 5 minutes and unreacted aldehyde 
functional groups were quenched using 10 mM glycine in PBS for 5 minutes. After PBS 
washing, the cells were blocked with 5% donkey serum (Jackson Immunoresearch) in PBS 
and incubated with anti-Fzd5 Ab against the N-terminal region (Sigma-Aldrich; 
SAB4503132; 1:100) or anti-Fzd5 Ab against the C-terminal region (Sigma-Aldrich; 
SAB4503134; 1:100) in 5% donkey serum, PBS, and 0.1% Tween 20 at 4°C overnight. 
Subsequently, the cells were stained with ultrasmall gold-DARabbit IgG (Nanoprobes; 
1:100) for 1 hour at room temperature and washed with PBS. The cells were then post-
fixed with 1% glutaraldehyde and 0.5% tannic acid for 30 minutes. Following silver-
enhancement of the gold particles, the cells were postfixed with 0.5% OsO4 in 100 mM 
phosphate buffer (pH7.3) for 30 minutes and dehydrated in a graded series of ethanol. 
After passage through propylene oxide, the cells were embedded in Epon 812. Ultrathin 
sections were cut, stained with uranyl acetate and lead citrate, and observed with a 
transmission electron microscope (JEM-1010C; JEOL).  
 
2-12. Statistical analysis 
 An unpaired two-tailed Student's t-test was used to calculate P values between two group 
of samples. Statistical significance is denoted by asterisks: * P < 0.05; ** P < 0.01; and *** 
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Table 1. 
 Gene 
Forward Primer Reverse Primer 
 5' - 3' 5' - 3' 
 Gapdh TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG 
 β-actin GCTCTGGCTCCTAGCACCAT GCCACCGATCCACACAGAGT 
 Nanog CAGAAAAACCAGTGGTTGAAGACTAG GCAATGGATGCTGGGATACTC 
 Esrrb TTTCTGGAACCCATGGAGAG AGCCAGCACCTCCTTCTACA 
 
Klf2 GCCTGTGGGTTCGCTATAAA AAGGAATGGTCAGCCACATC 
 
Klf4 GGAAGGGAGAAGACACTGCG ATGTGAGAGAGTTCCTCACGCC 
 
Rex1 GCTCCTGCACACAGAAGAAA GTCTTAGCTGCTTCCTTCTTGA 
 
Tbx3 AGGAGCGTGTCTGTCAGGTT GCCATTACCTCCCCAATTTT 
 
Sox2 ACCAGAAGAACAGCCCGGA  CCCGGGACCATACCATGA  
 
Oct3/4 CTCACCCTGGGCGTTCTCT AGGCCTCGAAGCGACAGA 
 
Fgf5 GCAGCCCACGGGTCAA CGGTTGCTCGGACTGCTT 
 
Otx2 CATGATGTCTTATCTAAAGCAACCG GTCGAGCTGTGCCCTAGTA 
 
Cdx2 GAGCTGGCTGCCACACTTG GCTTCTTCTTGATTTTCCTCTCCTT 
 
Gata3 CCATTACCACCTATCCGCCC TCGACTTACATCCGAACCCG 
 
Gata4 TCCATGTCCCAGACATTCAGACT AGCAGACAGCACTGGATGGAT 
 
Gata6 CCCCTCATCAAGCCACAGAA GTGACAGTTGGCACAGGACAGT 
 
Brachyury TGCTGCAGTCCCATGATAACTG ATGACTCACAGGCAGCATGCT 
 
Mixl1 GCACGTCGTTCAGCTCGGAGCAGC AGTCATGCTGGGATCCGGAACGTGG 
 
FoxA2 AGCCGTGAAGATGGAAGGG CTCCGCGTAGTAGCTGCTCC 
 
Sox17 GCACAACGCAGAGCTAAGCA CTGCCAAGGTCAACGCCT 
 
Pax6 AACCTGGCTAGCGAAAAGCA CCCGTTCAACATCCTTAGTTTATCA 
 
Nestin TGCAGACACCTGGAAGAAGTTC CCCAAGGAAATGCAGCTTCA 
 
Axin2 GGGAGCAGTTTTGTGGCAGCA  AGGGTCCTGGGTAAATGGGTGAG  
 









Dpm1 TGACCTGAAGTCCATGGCAG CTTAACTGCTTCCCAGCCCA 
Dpm2 AGAGGCTGAACATTGCTGGT CTTGTGACGGGACAGGACTT 
Dpm3 CGGAGCCAACATGACGAAGT CGTCCTCGCAGTCGTGAAAT 
Glt28d2 CGGCTCAGTCCTCTGTTGTG TATGACTTCTGCGTGCGGC 
Dpagt1 CCTGGTGGAACTGGAAGGTG GGTCTTGCTGAAGTGTCCCA 
Alg1 CCTGTGTGTGACCAATGCTATG GAGAAGTCCTCGTCCTCTGTCC 
Alg2  GAAGATATGGACCGCGCACT ACGTAGAGCGCCAGAAAGAC 
Alg3 TACGTACCCATCCACGTCCT TCTTAGGGAAGGACTCGGGG 
Alg5 TGGTTGACGATGGCAGTGAA CAGCGTTATCACCCGGACTT 
Alg6 TGCAGTGTTTGTTTCTTTCTTCAGT TCTGAGGAGGGTCCAGTGTT 
Alg8 CCTGCTGTGGAACTTTGGGT AAAGAGCAACGCCCCTTCAA 
Alg9 GTGCTCCACTCCACCTTGTT AAGGCCTGCTAGAAGTTGCC 
Alg10b CCTGTATCTGGTGTCGGTCG GCCTTGTTTCTGGGTTGCAC 
Alg11 CCAGGGCATTTGCTGGTTTC CCGATGGTCGCTTCAGACAA 
Alg12 CAGCCACGTCCCTCTATGTG GGACTCGATGTGTGTCCCTG 
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Alg13 AGAGCGTTTGTGACTGTCGG TCTCGAGGATCTGAACGCAG 
Alg14 CTATCTGTGTGTCCGCCCTG ACAATTCGCCCCAGGTACAC 
Stt3a AAGAATGAGGTGGCGAGTGG CACTGGTCACCCAAGTCGAA 
Stt3b TGGTGGGACTACGGCTATCA TTTTCCGACCAGTGCGATGT 
Uggt1 TCCCATGACTAAGGAGCCCA TACACCTGCCCAATCCGTTC 
Uggt2 TACAGAACATCGCGGGCATT ACATCATAGCGAGAGGCACG 
Gnptab CCTGATTGCGAAGGGCTAGT ATGGACACCATCACTCGCTG 
Gnptg AGAAACCACTCACTCTCAGCAC TAGTCCTGGGTCACTCCGC 
Nagpa GATCCCGTGAATCCGTTCGT CTCGTCACACTCGATGGCTT 
Mgat1 AGGACGGGCTTGTATTCGTC CAGGTCCAACTGGGTGAAGG 
Mgat2 TGACCCTAGAGATTGCCCCA GCCTCTCTGTAATGGCCGAA 
Mgat3 GTTCTGTATGGCTGGCCTGT GCTGGATACGAGGTTAGGGC 
Mgat4a CGCGTCCTCTTCTGTTTGGA ATGGGAAGAGTCCCTGTCCG 
Mgat4b CCTAACAGAGGATCCGCGAC AAGACGGTGGGCAGATGAAG 
Mgat4c TCTCACGATCTCCCACGTCT ATAGCCAATCGCAGGGCATT 
Mgat4d TTAGGAGCTGTTTGCAGCGA TTGAGGTGCTGTTCTCGTCC 
Mgat5 CCGGGTGCTAGACTCCTTTG AACTGCTGCGGGTTCAGATT 








Galnt1 GTGCTTCCCTCTTCTGTGGG CTTTGCCGCTGCTCTTGATG 
Galnt2 TTACTGTGGTGGACCGTTCG CCACTTCTGTCTGCTGTCGT 
Galnt3 ACGCAGGTGATTGCTCGTAA AGGTCTGGCACATACGCTTC 
Galnt4 ACCCTACGGGGGCTAATCTT CCGTCTTTGGGGCAGTTTTG 
Galnt5 GGTTGCTGAGGTTTGGCTTG GGTAAGGTTGCCCACATCCA 
Galnt6 GCTGTACCAGGGTTCCTTCC TGTGGTCTCCCATCTCGCTA 
Galnt7 CTGGGGAACCCGTCTGTTAC GAATCTTCAAGCCCCACGGA 
Galnt9 TCCCCATGACAAACCCAGGA GGCATTTTAACTTCTCGCGCA 
Galnt10 CGAGGCTGCTTGGAACAGTA GGAGGGATTGCAGGTGTTCA 
Galnt11 TTCTGCCTTACTGCGGACTG GGGGCTGTAACCACATCACA 
Galnt12 AAGCAAGCTCCCTATTCCCG GGGGATTGCGGTGGTAGTAG 
Galnt13 TCCGATGGTATCCTGTCCCT CCTCCACATTGCCAGATCCT 
Galnt14 GGGGTGGGGAGAACTTTGAAAT TCCTCAGGTTCAGCCTGTTCTC 
Galnt15 CGAGTGGGACACATCTACCG AGATGGGTACAGCTCAGGGT 
Galnt16 CCGGACTGACCCCACTAAAC TGCCACCACACATCCATACC 
Galnt17 AATTGGTCTGCTGGACCCTG ACGGTTTCTTCTTCCGCTCA 
Galnt18 TTGGTGTCCACTTGCGTGAT GCTGGCGATGTAGTTGGTGA 
Galntl5 CATCGAGAGAGAGGTGCCAG GAGGTTCACCACACTCGACA 
Galntl6 GGAGCCTTCGACTGGGAAAT GAGACCTCCAGCCATAACCG 
C1galt1 GCAAGGCATTCAGATGACAA ATGTTGGCTGGAATCTGCAT 
C1galt1c1 GCAAGCCCCTAACAAAGACG CCGGAAACTCTTACTGAGCTCC 
Gcnt1 TTCCAACGGTGCCCCTTATC AGCATCCAGCTCAAGTCACC 
Gcnt3 CACCCTCCAGCGTGCC TCAAATTTTCGATGCAAGGGAT 
Gcnt4 ACGGAGCATCATCGACTTGG TGTGGACGACCAGCGAATAG 
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A4gnt AAAGACTTCCACGGGTTGGG CCACAAATGCAGTGCGTAGG 
B3gnt6 AGTCCCACGACACTGGCTTTC CCTGCCTGTGTTCCTGGAGG 
Pomt1 TATGAGAATGGCCGTGGCAG GGGCAGGCATGGAGATGTTA 
Pomt2 TGGGAAAGATGCTGATCGGT TCGTATCTGTCCCCAGGCTT 
Pomgnt1 TGGACACTCGGAGAGCAATC GTATGTGTCAAACACGCGCT 
Pomgnt2 GTGCCTTACATGCTGACCCT AACTGTGGACCTGGGAAAGC 
B3galnt2 TCGGTGTTCTTAGGTCCCCT ACCAGCCAGTTTCGCATTGG 
Pomk TCGCCAGGCATTTTGTGAAAG TACTGGCCTTCTACAGCCGA 
Fktn GTGGCAACTACCTCTGGCAT CGCCCGAGCTTCCTTATACC 
Fkrp CTCTAGTGCCTGATGGAGCG CCGAGAGGTTGAAGAGGTCG 
Rxylt1 GGAGGCTTTGTGGATCTGCTT TGTCCAGCTGGCTTCAACTAC 
B4gat1 GGTGCCTGCATTTGAAATCC TGCACCAGCTCGTTCTTGTT 
Large1 CCAGGACCCACTGCACTTAG CCCTCATAATACTTTCTTGGCCTTG 
Large2 ACCTGCCTACTCCCTCTACG GCACCACCAAAGCAGTCTTG 
Pofut1 AGGCAGTCGTCCTTCTTTGG GGAGGTGGGCTGCTTTGTAT 
Rfng ACTCGCACCTGGAAAACCTG GGACCCCCATAGCTCAAGGT 
Mfng ATTCCGCTCCCTCCATTGTC ACACCAACTCAAGCGTTCCT 
Lfng TGTCCATTGCCACCTGTACC AGTTAGGGACAGACCTGCCA 
Pofut2 CGAAGAAACACGGGGTCTGA TCTTATCAGCGGCATCCGTC 
B3glct GGAGGCGGGATGGTCTTTAG TGGGGTAATCTACTGGCCGA 
Eogt GCTGGCCTTACCCACTTACTT CAGCGCTCATCTTCACAGTTG 
Ogt GAAAGAGGCACGCATTTTTGA ACCACCGCATGATTTGGG 
Poglut1 TTGTGCGGTTCACTGGTCTT GGTCGGTCTTGACTGGGATG 
Poglut2 TGGTGAGCACGTTGGCTTTA AGTCAGGTCGTAGGTAGGCA 
Poglut3 TCCTCAAGCAGGAGTCACCA GCTGGGGAACAAGCTCCATT 
Gxylt1 CACGTACTGGGGCTCATGTT TGGGCGCAGATCCTTTTGAT 
Gxylt2 ACGACGACAAACAACCCACT CTTCTCGTAAGCCCTTCGCA 





Xylt1 CTGACCGATTCCAGGGCTTT GGGACTTGCGACCTTGAAGA 
Xylt2 GGACAACACCTTCACTCCGA GGGCACAGACTTGGGCATTA 
B4galt7 CATTCTGCTGCTGTCCAAACA GCCCCAGCCCCAAAAG 
B3galt6 CCCAGAGGACATGTTGGAGAA AACTGCACCTCATGCTTGCA 
B3gat3 CCTACAGCCGGGAGCTCTTT CCCACAGGCCACACTGAGA 
Ext1 CAGGCTTGGGTCCTTCAGATT CCATCCGTTGCTGAGCATT 
Ext2 CCCACAGAGGCAGATTGAAGA TGGCTTTAATGGACTGGAAGTATG 
Extl1 AGCCTTCAAGACTTCCCCTTTT GATCACGGCGCTGAAACTG 
Extl2 TGAGAAACCGACTCCAGGTCTT TGAGTGTGTCATCGTCTACCATCA 
Extl3 ACCTTTTGTGGCCAGACATTG AACCGATTGTTCAAACTGTTCT 
Hs2st1 TGGCGTATCTGTACCCCTGA ACCCACATCACAGCTCACTG 
Hs3st1 CTACAAGGCTCTCAACCGCA CGGCCTTTGGACTCGTGTAA 
Hs3st2 CCACAGAGCGTCCCCAGAAA AGCATCTCCCGGTATTAAGCG 
Hs3st3a1 CCTTACTTCTGGACGAGGGC TCTGGGCATCAAATCCCGGT 
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Hs3st3b1 AGCTACCACAAGGGTCTTGC CATGGTGATCTGTCCCTTGA 
Hs3st4 GTGACGAATGAGGCTCCCAA GAGTCGCTCACCACTGACAA 
Hs3st5 CCAGAGTTGGGAGCTTGG CACCACCAAATCGACTTTCA 
Hs3st6 CTGTTTGTAAGCGGTGAGCG AGGGGAAGCCCTTAGTAGCA 
Hs6st1 CTGACTGGACCGAACTCACC GAACTTTCTGGGCGAACGCA 
Hs6st2 ACCTGACTCTAGTGGGATGCT AACAGGTACTGGGTCTTGCG 
Hs6st3 TCAACATCAAAGGGCGGGAT CATGGCTGCTCCAGACGAAT 
Ndst1 GTATGAGGCCTGGAAGCAAGT GCCGGCTTCAGATGTGGGTA 
Ndst2 CGCTGGCTGACTTACTATCCCT CCGGGTTGACACGAAGCT 
Ndst3 TCCCAAGACAAACCTGTGGG AAGAAGAGCTCCCCTCCATGA 
Ndst4 ATTCCGATCAACCTGGGCTAC GGTGACCTGAATACCCCAGAC 
Glce AGGAACAACAGAAGGCACCC AGCCCTAACACCTTGCTTCC 
Csgalnact1 ACAGCCAGGGAAGAAGGTATTTT TCGTGATGGCCGTAGATTACG 
Csgalnact2 GACCTGTCAATATCAATCGGATTTC TTCTCCACCCCAGCCTTTTA 
Chpf GCCGCTGCATCCTTGATG CTCAGTTCCAGGTAGTTGTAGTGCAT 
Chpf2 AGGGTGAGGGAGAAGATCCC ATACCGAGTCCTGAGCACCT 
Chsy1 CCGGGAAGGTGGAGTTCTTC TCTTCTGGGGTGGGTAGGAG 
Chsy3 GAAGGTGTGTTCGCCGTTTC GCTGTTGTGGAGGTCTTGGA 
Dse CCCACAGCTTCTCCTTCTTG CTCCTCAAAAGGGACATCCA 
Dsel GAGCTTCTGGATGTATGGAG CTGAACCAGGGAGTGAGG 
Chst3 CTGACCCAGCCCTGCTCTT AAAAGGTGGAATCCAACTCGC 
Chst7 TGGGCGAACTCTTCAACCA GATACAGTGCCTGCCACAGATG 
Chst11 CCAGAGATCAACCACCGCTT TTCTGCGTGAACTTGTTGCG 
Chst12 TCGGTGAGTGAGGCTTTCAG GCCGTCCTGTTCCGATAACT 
Chst13 CCAGGAGGTCTGGAACGAAC AGCAACCTGTACCCTACCCA 
Chst14 GCCTGCTCTAACTGGAAACG CTGCCAGAAACACCAAGTCA 
Chst15 TATGACAACAGCACAGACGG TGCAGATTTATTGGAACTTGCGAA 
Ust TTGGGGTCATTGGGAGATGC GTGCCTTGTGGTAGAGCCAT 
B3gnt7 GGCCACGAGGGCTTCAA CCTTGTTCATCCGGCTGCT 
Chst1 TGTGCGCATGTGTGGCTT TGACTGCGCTCACGACAAG 
Has1 CATGGTGCTGCTGTCACTCT GCAACACGGGGACGTAGTTA 
Has2 GGCCGGTCGTCTCAAATTCA ACAATGCATCTTGTTCAGCTCC 





Ugt8a TATCGGCAGAGGGCTCAGAA TGATGGACAGCAGAACGGAG 
Ugcg GAGCCAGCCCATTTGCCTAA GGAAATGCTGTTTGGCCCAG 
B4galt5 CCATCGAGGAGAGGTCCAGTT CTTGCCGCTCCTTTGACTTC 
B4galt6 GGGTCTCCAATCGCTCTCTG AGAGGTACGTGTTGGCGATG 
A4galt GAGGAGACCATGTCCAAGCC TGAAGAAGGTGAAGACCCGC 
B3galnt1 CCTTGGAGGATGAGCACGTT ACTTGGCATTGGGGCAAAAC 
Gbgt1 TGAACCGCCACTTCATCTGG CCGAGGCTTCCTTTCATCCC 
B4galnt1 TGTACTCCAGCACCCGAAAC GATCCTGACCGGGATGTGTG 
B3galt4 CTCAGAGTCAGCAGCACACA GATGTAGCGGGCCATAGGAC 
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B4galt1 GCTGGAGACACCATGTTCAATC ACAAAGCAGTTGTAATCATAGTCCT 
B4galt2 GAGACCTTCAACCGAGCCAA ACAACGGTACAGATTGCGGT 
B4galt3 CCATAATTGTGCCCCATCGT GGTGCAGGTGATAGAGCAGCA 
B4galt4 TCTTTACCCTGTGCCTGACG GTCCTTTGCCTTGGGGATCA 
B3gnt2 GGGTCTTCCTGTTGGGCAA AAACTTAAGCATGTCCGAAAGGTC 
B3gnt3 TACGGCGACATTCTCCAGTG CACATCGTCGTCCCCATTGA 
B3gnt4 TCTGAAGGAGCGCATACCAG CTATGGTGGGACCTTGGCAG 
B3gnt8 GACTGTCAGACTTGGGGGAC AGTGGAAAGCTCCTACAGGC 
B3gnt9 CGACAGAGTGGATGAAGGAAGGATA CTCCTCCTCCTCCTCATGTCCA 
B4galnt3 GGGCCATATCCCACAGACAG CACTCGAAAGAGGGTGTCCC 
B4galnt4 GGACCCACATGGTTACTGGG GTGGTGGTAGAAGTGTCGCA 
B3galt1 CAATCAGGGATGTCCGCAGT AGAACGGTGGGTAGTTGCTG 
B3galt2 AGCTCCTCAGACTCTGAGGCC TGTGACTCCCTGTGGTGATAGC 
B3galt5 CACTCACCGGCTGCTCTTTA ATGTGAGCCATCTTTGCCGA 
Gcnt2 CTCCATGCCACCAAACGCA CTTCGCTTCCATGTCCATCCAC 
Gcnt7 GCCCACCCCACAATCTAACA ACGGGGATCAGTTAGGACGA 
Mgat5b GGCCGTCCTCAACAAGTACA CCGGAAGAACTCGTGGTTGA 
Ggta1 ACCTATGAGAGGCGGGAACT ATGGCCGCGTGGTAGTAAAA 
























St3gal1 AACCCAACAACCTGAGCGAC GGATCCACATTGCCAGGC 
St3gal2 ACTGGCACCACTACTGGGAGA ATGCACGCCTGTCTTCCG 
St3gal3 GACTCTAAACTGCCTGCCGA TGCGAAAGGAGTCATCCAGG 
St3gal4 AGCCTCGAGTGTCGTCGCT AGCGAGCTGTTCCGCAAC 
St3gal5 GCTTTGGCTACGACCTCAGT GTTTGCCGTGTTCCGAGTTC 
St3gal6 TCCCAAGGATCAGAAACCCA CACTGCATATGTGAAAGGCCA 
St6gal1 TCAAGTTCAGCGTAGAGGCG AAGACACGACGGCACACTTA 
St6gal2 CCACCCTGAGAACCCTTTCC GCGCTTTGTGATTTCCTCCC 
St6galNAc1 GAGAGGCAGTCCAAGGAGAGC TGAGGATTCTCTGGTGCTGGC 
St6galNAc2 GAGCCGACTTTGCCAACACTC GGGTGGAGAGGTCAAACAGGC 
St6galNAc3 CCAGTGTCCCTCTCTTGCTG TCCTCATGTTGCGGAAAGGG 
St6galNAc4 CAGGCAAGAACCGGAGACAA TAGACCACGATCTCCTCGCA 
St6galNAc5 AAGGGCAGTCATCACCGTTT ACAGCGGGTGATTCTGGTTT 
St6galNAc6 CCCGAACATGGAGGCCTAT AAGAGGTCGTCAAACTGCTGC 
St8sia1 GTGACCCTGCCCATCTCTTTG CCATCGTACCACAGGCTCTTC 
St8sia2 AATTCTGGAGGCAGAGGTACAAT GCGTCTGGTTGTGTCTCCA 
St8sia3 GGGCGCCCCGAATG CTGGTCTAGAAACTTCAGTGCAAACT 
St8sia4 TGGCTCCACCATCTTCCAAC TTTAGTGTCCGGCGTCTGTC 
St8sia5 AATACATGCTGGACGACTTCCA TGCTCAGGTACTGCGGGTG 
St8sia6 TTGTCCACACTCGTGAAGGG AAAGGTGTCGGTGGGACATT 
Fut1 CCCGACACAAAGACCCCATC AAGTGCAAAGTCCTTCCCCG 
Fut2 AGACCTGTCCCCACTCCTTA ACCAAGTGACTCCTTCTGCC 
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Sec1 CCTTCCACACGGTTTTCAAGC CTACTGTGTTTGGCTGTCCCA 
Fut4 ACGTGTCTGTGGACGTGTTT AGCCAGGGAAGCAGCATTAG 
Fut7 CAAACCCGGCAATCTCTCCT AGTTGAAGATGCCCCGGAAG 
Fut9 GCCCTGGATCTTTCCTCACC TCTAAAGCGATCCCAGCGAG 
Fut10 CCCTTTGTCAGTCATCCGGG GGCTCCAGGTGTTTAGGCTC 
Fut11 CGCTACATCCCGGTGGATTC CCGTGGCTGTGTCCTGTAAT 
Abo ACTCGATGGCAGGATGTGTC CCACCTCACGTAGAAAGCGT 
B3gat1 GTTGGTGGCCTTCGGTATGA CCCTTCACACCACGTAGCTT 
B3gat2 GCTGTATTTAAGCGCCGTGG ACGAGAACCTTGGTGCAGTT 
B4galnt2 CTTGACGGCTTTCCCGG TGTGAGCCAAGAAGAAGTTCACC 
Chst2 TGCCCACCTCAACGCCT CCTTGATAACCAGCGTGCG 
Chst4 CGTCCACAGACACCTTTCCC AAGACAGCACCAGCACATGC 
Chst5 CGGAGCTTGAGCAAAGGG CCACTTGAAACTGTCCATGCCT 
Chst8 CTGACCAACCTCGACCTCAC GTTTCGGACGAGTTGTTGCC 
Chst9 TCACAAAGGGAGAACGGAGC ATGACCGACGCTTCTCTTGG 
Chst10 GTACCGGAAGAACCGGACAG ATCTGCCTCCAGGGTCTCAT 
Gal3st1 AACCACATGCGCTTCCACTA GGCACCACGGATCCAAAGTA 
Gal3st2 AGCCCAAGAACCTGACACAC AGAATATTGGCCTTCCCACCC 
Gal3st3 CACCATGCCACCTATCCTCC AACTTGGGGTACCAACTGAGC 





Slc35a1 GCGAAGTTGAGTGTGCCATC AAGCAGTGCAGGGGATCTTC 
Slc35a2 GGCTGTCCTGGTCCAATATGT ACTGGAGGTTATTCTGCAAGGT 
Slc35a3 TGGATTCTCACAGTGGTGCC GACGGACACACTTCATCCTGA 
Slc35b1 CATCATCACCACAACCCGGA TTGGCATCAAGACCGAGACC 
Slc35b2 GGACAGAGACAGCGGAATCC ACCCGAGGCACAGAAGACC 
Slc35b3 CTGGTTTACCCTCGCTGACA CCGAGTTGGAAGCATTGTGC 
Slc35b4 TCGCACTTGTTGCTACCGAT GAATGTTGGCTGTGCTGCAA 
Slc35c1 GCCACCATCCTGTTCTCCAA GAACAGAGGCTGAGTGGACC 
Slc35c2 GTCTCCACTTGTCCACCTCTG AACTCGGAGAAGCCCAAACC 
Slc35d1 TGTTTGCTGAAGGCGCTCTA GCTACGAAGGCTCCGATGAT 
Slc35d2 AGACCAGAGGTCCCACACAT GCTCATTGTGCAGTGACGTG 
 
Table 2. 
Class Ab/Lectin Source Dilution 
  H3 Cell Signaling; #9715 1:100 








GNA EY Laboratories; BA-7401-2 1 μg 
LCA VECTOR Laboratories; B-1045 1 μg 
ConA Cosmo Bio; J203 1 μg 
PHA-E4 VECTOR Laboratories; B-1125 1 μg 
PHA-L4 VECTOR Laboratories; B-1115 1 μg 
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VVA-B4 Kindly gifted by Prof. Yamamoto 1 μg 
HPA EY Laboratories; F-3601-1 10 μg 
PNA Cosmo Bio; J514 10 μg 
PNA Cosmo Bio; J214 1 μg 
MAH Kindly gifted by Prof. Yamamoto 1 μg 
MECA-79 Santa Cruz Biotechnology; sc-19602 1:5 





JM403 Seikagaku Corporation; 370730 1:100 
Hepss-1 Kindly gifted by Prof. Yoshie 1:50 
mCochlin-Fc Kindly gifted by Prof. Yamamoto 1:10 
CS-56 Sigma Aldrich; C8035 1:100 
MO-225 TCI chemicals; A2872 1:50 
LY111 TCI chemicals; A3143 1:10 
R-10G  Kindly gifted by Prof. Kawasaki 1:100 





CD77 BD biosciences 551352 1:50 
Choleratoxin subunit B Sigma Aldrich; C1655 1 μg 
SSEA-3 Abcam; ab16286 1:10 
Forsmann antigen Santa Cruz Biotechnology; sc-23939 1:100 
















ECorL Kindly gifted by Prof. Yamamoto 1 μg 
WFA Kindly gifted by Prof. Yamamoto 1 μg 
MAL-I Kindly gifted by Prof. Yamamoto 1 μg 
SNA EY Laboratories; F-6802-1 10 μg 
SNA VECTOR Laboratories; B-1305 1 μg 
735 Absolute antibody; Ab00240-1.6 1:100 
AAL VECTOR Laboratories; B-1395 1 μg 
SSEA-5 MACS Miltenyi Biotec; 130-106-129 1:11 
SSEA-1 Immunotech; 1954 1:3 
SSEA-1 Beckman Coulter; IM1423U 1:3 
 Alexa Fluor 488 anti-mouse IgG Life Technologies; A-11001 1:300/10000 
 FITC anti-mouse IgM Sigma Aldrich; F9259 1:300 
 Alexa Fluor 488 anti-rabbit IgG Life Technologies; A-11008 1:300/10000 
 Alexa Fluor 488 anti-rat IgM Invitrogen; A-21212 1:300 
 FITC Streptavidin Biolegend; 405201 1:300 
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3. Results 
3-1. ESC differentiation to EpiLCs 
To examine the glycosylation dynamics occurring during the transition from naïve to 
primed pluripotency, we differentiated EpiLCs from ESCs. ESCs and EpiLCs maintain the 
pluripotent state by LIF and FGF signaling, respectively (Niwa et al., 2009; Lanner and 
Rossant, 2010).  A previously established protocol (Hayashi et al., 2011) with slight 
modifications was used to induce EpiLCs differentiation (Fig. 3A). Compared to ESCs, 
EpiLCs exhibits a typical flattened morphology after 72h of induction (Fig. 3B). Real-time 
PCR analysis showed a negligible change in the pluripotency marker Oct3/4, whereas 
genes associated with the naïve state, such as Nanog, Esrrb, Klf2, Klf4, Rex1 and Tbx3 
were substantially downregulated, together with a striking increase in the primed markers 
Fgf5, and Otx2 (Fig. 3C), consistently with previous results (Hayashi et al., 2011; Du et al., 
2018). Oct3/4 protein was retained in EpiLCs at levels similar to those in ESCs, while the 
Nanog decreased and Otx2 increased. Moreover, the phosphorylation level of ERK1/2, a 
downstream kinase involved in FGF signaling (Lanner and Rossant, 2010), was 
significantly higher in EpiLCs (Fig. 3D). The expression of these markers was further 
assessed by immunostaining: Oct3/4 staining slightly decreased during the transition from 
naïve to primed, whereas Nanog was not detected and Otx2 was strongly expressed in 
EpiLCs, confirming the successful differentiation of EpiLCs from ESCs (Fig. 3E).  
 
 
(see legend in the next page) 
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Fig. 3. ESCs differentiation into EpiLCs.  
(A): Schematic representation of EpiLC differentiation protocol. (B): Cell morphology of 
ESCs (upper panel), and EpiLCs (lower panel). Scale bar, 200 μm. (C): Transcriptional 
analysis of pluripotency (red), naïve (grey), and primed (blue) markers normalized against 
Gapdh in ESCs and EpiLCs, and shown as a fold change relative to ESCs. (D): 
Representative image of a western blot analysis of p-ERK1/2, ERK1/2, Oct3/4, Nanog, 
Otx2 and Gapdh. (E): Representative image of permeabilized ESCs and EpiLCs using 
anti-Oct3/4, anti-Nanog and anti-Otx2 Abs. Nuclei were stained with Hoechst. Scale bar, 
10 μm. Values are shown as means ± s.e.m. of three independent experiments. 
 
3-2. Glycosylation dynamics in pluripotent stem cells 
3-2-1. N-linked glycosylation 
N-linked glycosylation involves the transfer of a tetradecasaccharide core unit from a lipid-
linker donor to an asparagine of nascent proteins at the endoplasmic reticulum (ER). 
Following transfer, the N-glycan undergoes trimming and a quality control process. Fully 
folded N-glycans are transported to the Golgi where they are subjected to processing 
before transportation to the plasma membrane, whereas misfolded proteins are recycled, 
resulting in the release of free oligosaccharides (FOS) (Weerapana and Imperiali, 2006; 
Hirayama et al., 2010) (Fig. 4A). N-glycans and FOS composition was measured by mass 
spectrometry (MS) analysis. The total amount of N-glycans was similar between ESCs and 
EpiLCs. Among the detected N-glycan subclasses, namely high mannose-type (HM), 
pauci-mannose (PM), and complex/hybrid (C/H), HM structures were the most abundant in 
both ESCs and EpiLCs, confirming previous results obtained in conventional hESCs and 
hiPSCs (Fujitani et al., 2013). The total amount of fucosylated N-glycans was higher in 
EpiLCs compared to ESCs and was characterized by increased levels of both fucosylated 
PM and C/H structures. Total sialylated N-glycans, mainly present in an α2,6 configuration, 
were enhanced in EpiLCs (Fig. 4B; Fig. 5). FOS amount were reported to increase under 
ER stress condition (Hirayama et al., 2010). A substantial reduction in the total amount 
and relative percentage of FOS was observed in EpiLCs, indicating a reduction of ER 
stress upon transition from ESC to EpiLC (Fig. 4C; Fig. 6). Notably, a recent study showed 
that ER stress promotes interleukin-6 family expression, including LIF, in mouse astrocytes 
and macrophages (Sanchez et al., 2019), suggesting a connection between FOS, ER 
stress, and LIF expression in ESCs. Real-time PCR analysis of N-glycosylation pathway-
specific genes well correlated with MS data. Indeed, Fut8, the sole enzyme responsible for 
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catalyzing N-glycans core fucosylation (Wang et al., 2005), showed an increased 
expression. Interestingly, a significant enhancement of Uggt2 was observed in EpiLCs, 
suggesting that a reduction in FOS-mediated ER-stress is partially mediated by increased 
expression of enzymes involved in N-glycans quality control and folding (Fig. 4D). To 
obtain more details, a FACS profiling using a set of lectins that recognize different N-
glycan structures was performed. As a result, we observed a shift to shorter HM by 
galanthus nivalis agglutinin (GNA). Moreover, the increase in core fucosylated N-glycans 
observed at the structural and transcriptional level in EpiLCs was further confirmed by lens 
culinaris agglutinin (LCA) staining. In addition, phaseolus vulgaris erythroagglutinin (PHA-
E4) and phaseolus vulgaris leucoagglutinin (PHA-L4) staining indicated an enhancement 
in N-glycans carrying bisecting GlcNAc and 2,6-branching in EpiLCs, suggesting a 
relevant role for these structures during EpiLC differentiation (Fig. 4E; Fig. 7). Collectively, 
HM structures and core fucosylated N-glycans not carrying bisecting GlcNAc are observed 
in ESCs, whereas short HM structures and core fucosylated N-glycans carrying bisecting 
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Fig. 4. N-glycosylation comparative analysis in ESCs and EpiLCs.  
(A): Schematic diagram of the N-glycosylation pathway. The asterisk denotes enzyme 
putative activity. (B): Absolute amount of N-glycans detected by MS. High mannose (HM), 
pauci-mannose (PM), and complex/hybrid (C/H). Fucose: Fuc; sialylation: Sia. (C): 
Absolute amount of FOS detected by MS (left panel) and FOS percentage relative to total  
(legend continues in the next page) 
 - 22 - 
N-glycans (right panel). (D): Transcriptional analysis of N-glycosylation-specific enzymes 
normalized against Gapdh and shown as a fold change relative to ESCs. (E): N-glycans 
profiling by FACS using specific lectins. Lectins specificities are stated below the labels 
and schematically represented above each histogram. The grey line at the bottom 
represents the negative control staining. (F): Model of N-glycome alterations during naïve 
to primed transition. Values are shown as means ± s.e.m. of three independent 
experiments in (D), (E) and four independent experiments in (B), (C).  
 
 
Fig. 5. N-glycosylation MS spectra.  
Representative N-glycans MS spectra of ESCs and EpiLCs. To allow intensity comparison 
across ESCs and EpiLCs, MS signals in ESCs and EpiLCs spectra are scaled to the same 
I.S. (internal standard) signal area. Representative estimated structures are shown.  
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Fig. 6. FOS MS spectra.  
Representative FOS MS spectra of ESCs and EpiLCs. To allow intensity comparison 
across ESCs and EpiLCs, MS signals in ESCs and EpiLCs spectra are scaled to the same 
I.S. (internal standard) signal area. Representative estimated structures are shown.  
 
 
Fig. 7. FACS profiling of N-glycan structures.  
Representative FACS histograms. Negative control: grey; ESC: black; EpiLC: blue. 
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3-2-2. O-linked glycosylation 
O-linked glycosylation is characterized by the initial addition of a monosaccharide to the 
hydroxyl group of a serine/threonine residue on the target polypeptide. Various 
monosaccharides can be added to serine/threonine giving rise to different two major O-
glycosylation subclasses: mucin-type O-glycosylation and not mucin-type O-glycosylation. 
Mucin-type O-glycosylation is initiated in the Golgi by a large family of up to 19 
transferases in mouse that add N-acetylgalactosamine (GalNAc) on a serine/threonine 
residue to form Tn antigen. Tn antigen can be further elongated into one of 4 distinct core 
extensions: T antigen (Core 1), Core 2, Core 3 and Core 4 (Bennett et al., 2012). Not 
mucin-type O-glycosylation takes place in the ER, except for the O-linked β-N-
acetylglucosylation (O-GlcNAcylation) catalyzed by Ogt, the sole glycosylation that occurs 
in the cytoplasm and nucleus (Torres and Hart, 1984) (Fig. 8A). O-glycome profiling by MS 
revealed that HexNAc (Tn antigen or O-GlcNAc) was the most prominent O-glycan 
structure in both ESCs and EpiLCs. Moreover, T antigen and its modified structures were 
the only detected O-glycans among the mucin-type O-glycosylation core structures in both 
ESCs and EpiLCs (Fig. 8B; Fig. 9), indicating that the T antigen elongation pathway is the 
most abundant during early embryonic development. Transcriptionally, a substantial 
upregulation of both mucin-type O-glycan and not mucin-type O-glycan-specific genes was 
observed in EpiLCs. In particular, the expression of Galnt3, one of the enzymes involved in 
the formation of Tn antigen, was dramatically increased (Fig. 8C), suggesting its possible 
major involvement in the formation of Tn antigen in EpiLCs, similarly to previous 
observations in trophoblast stem cells (Raghu et al., 2019). FACS profiling showed a shift 
from short mucin-type O-glycans, as indicated by Vicia villosa agglutinin-B4 (VVA-B4) and 
peanut agglutinin (PNA), which recognize Tn and T antigens, respectively, to elongated or 
branched mucin-type O-glycan structures, as shown by MECA-79 antibody (Ab) staining in 
EpiLCs. Intracellular O-GlcNAc was present in both ESCs and EpiLCs, despite it increased 
in EpiLCs, reflecting Ogt expression upregulation (Fig. 8D,E; Fig. 10). 
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Fig. 8. O-glycosylation comparative analysis in ESCs and EpiLCs.  
(A): Schematic diagram of the O-glycosylation pathway. (B): Absolute amount of O-
glycans detected by MS. HexNAc: GalNAc or GlcNAc. (C): Transcriptional analysis of O-
glycosylation-specific enzymes normalized against Gapdh and shown as a fold change 
relative to ESCs. (D): O-glycans profiling by FACS using specific lectins/Abs. Lectin/Ab 
specificities are stated below the labels and schematically represented above each 
histogram. The grey line at the bottom represents the negative control staining. (E): Model 
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of O-glycome changes during naïve to primed transition. Values are shown as means ± 
s.e.m. of three independent experiments in (C), (D) and four independent experiments in 
(B).  
 
Fig. 9. O-glycosylation MS spectra.  
Representative O-glycome MS spectra of ESCs and EpiLCs. To allow intensity 
comparison across ESCs and EpiLCs, MS signals in ESCs and EpiLCs spectra are scaled 
to the same I.S. (internal standard) signal area. Representative estimated structures are 
shown.  
 
Fig. 10. FACS profiling of O-glycan structures.  
Representative FACS histograms. Negative control: grey; ESC: black; EpiLC: blue. 
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3-2-3. Glycosaminoglycans 
Glycosaminoglycans (GAG) are polysaccharides consisting of repeating disaccharide units 
attached to a core protein. Heparan sulfate (HS), chondroitin sulfate (CS) and dermatan 
sulfate (DS) are connected to a serine of the core protein via a tetrasaccharide linker and 
are categorized by their different disaccharide unit composition, sulfation and 
epimerization. Keratan sulfate (KS) is a sulfated polylactosamine chain extended from a 
GlcNAc on N-glycans or O-glycans. Conversely, unlike all the other GAG classes that are 
synthesized in the Golgi on core proteins, hyaluronan (HA) polymerization occurs at the 
cell membrane and is not linked to any protein (Lindahl et al., 2015-2017) (Fig. 11A). GAG 
quantification was performed by high-performance liquid chromatography (HPLC). A sharp 
increase in the total amount of GAG in EpiLCs was observed. Especially, HS and CS/DS, 
which represent the vast majority of detected GAG, were strongly upregulated, whereas 
HA levels did not differ between ESCs and EpiLCs; KS and 3-O-sulfation of HS could not 
be detected due to technical limitations. The absolute amount of HS sulfation was 
substantially higher in EpiLCs, with a specific increase in mono-sulfated 6S and di-sulfated 
2SNS, indicating that variations of the HS sulfation pattern occur from early developmental 
stages. An overall higher level of CS/DS structures was observed in EpiLCs, with 
predominancy of Unit A, followed by Unit C and unsulfated Unit O (Fig.11B; Fig. 12). Real-
time PCR analysis of GAG-specific genes well correlated with HPLC data. Indeed, 2SNS 
and 6S sulfation enhancement in EpiLCs was followed by a significant enhancement of 
Ndst2-4 and Hs2st1, and Hs6st2 expression, respectively (Fig. 11C). FACS staining 
confirmed the results obtained by HPLC. In addition, increased staining of di-sulfated CS, 
high-sulfated KS and 3-O-sulfated HS were observed in EpiLCs, consistently with the 
striking enhancement of Ust and Chst15, Chst1, and Hs3st4-6 expression (Fig. 11D; Fig. 
13). The HS sulfation pattern has been shown to be critical for growth factors binding and 
downstream signaling. Consistent with the present observations in EpiLCs, N-sulfation and 
3-O-sulfation were reported to be required for exit from the naïve pluripotent state via FGF 
and first apoptosis signal receptor (Fas), respectively (Nishihara, 2018). In conclusion, the 
ESC GAG profile is characterized by unsulfated HS, mono-sulfated CS and low-sulfated 
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Fig. 11. GAG comparative analysis in ESCs and EpiLCs. 
(A): Schematic diagram of the GAG synthetic pathway. Asterisks denote enzymes whose 
contribution to biosynthesis remains unclear. (B): Absolute amount of GAG detected by 
HPLC. Heparan sulfate (HS), chondroitin sulfate/dermatan sulfate (CS/DS) and 
hyaluronan (HA). (C): Transcriptional analysis of GAG-specific enzymes normalized 
against Gapdh and shown as a fold change relative to ESCs. (D): GAG profiling by FACS 
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using specific Abs. Ab specificities are stated below the labels and schematically 
represented above each histogram. The grey line at the bottom represents the negative 
control staining. (E): Model of GAG modifications during naïve to primed transition. Values 
are shown as means ± s.e.m. of three independent experiments. 
 
 
Fig. 12. GAG HPLC chromatogram.  
Representative GAG HPLC chromatogram of ESCs and EpiLCs. To allow intensity 
comparison across ESCs and EpiLCs, HPLC signals are scaled to the same I.S. (internal 
standard) signal area. Estimated structures are labeled on the chromatogram.  
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Fig. 13. FACS profiling of GAG structures.  
Representative FACS histograms. Negative control: grey; ESC: black; EpiLC: blue. 
 
3-2-4. Glycosphingolipids 
Glycosphingolipids (GSL) are characterized by the initial addition of glucose or galactose 
to a ceramide unit to form glucosylceramide (GlcCer) or galactosylceramide (GalCer), 
respectively. GlcCer synthesis occurs in the Golgi, where it is further processed to 
lactosylceramide (LacCer), which is the branching point for the formation of the globo (Gb), 
ganglio (Gg) and neolacto/lacto ((n)Lc) series. Conversely, GalCer is formed in the ER and 
is the precursor of the gala-series (Schnaar and Kinoshita, 2015-2017) (Fig. 14A). GSL 
composition quantified by MS showed a marked reduction of total GSL in EpiLCs. A shift 
from Gb and (n)Lc to Gg series was observed during ESC differentiation into EpiLCs (Fig. 
14B; Fig. 15; Table 3). GlcCer and GalCer could not be detected due to the inherent 
enzymatic specificity of the EGCase used to release the glycan moieties (EGCase I). The 
Gb to Gg series switch in EpiLCs observed at the structural level was consistent also at 
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the expression level. A reduction in the expression of the Gb series-specific enzyme 
B3galnt1 was followed by a robust upregulation of the Gg series-specific enzyme B4galnt1 
(Fig. 14C). Moreover, FACS profiling further confirmed the shift from Gb to Gg observed 
(Fig. 14D), demonstrating that the Gb to Gg series switch previously observed in neurons 
and embryoid bodies derived from mouse and conventional human ESCs, respectively 
(Liang et al., 2010; Russo et al., 2018), occurs specifically during the naïve to primed 
transition. The GSL profile dynamically changes during embryonic development; as a 
result, specific GSL structures, such as stage-specific embryonic antigen (SSEA)-3, 
SSEA-4 and Forssman antigen, are used as developmental stage markers (Russo et al., 
2018). FACS profiling showed that SSEA-3,4 and Forssman antigen staining mildly 
increased in EpiLCs (Fig. 14D; Fig. 16). However, SSEA-3,4 and Forssman antigen are 
structures of the Gb series (Fig. 14A), which we showed to be drastically reduced and 
undergo a switch to Gg series upon ESC differentiation to EpiLCs, thus suggesting that Gg 
series structures might be more suitable developmental stage markers. Together, these 
data show that the GSL composition shifts from Gb and (n)Lc to Gg series during ESC 
differentiation into EpiLCs, and demonstrate the presence of SSEA-3,4 and Forsmann 
antigen structures in both ESCs and EpiLCs (Fig. 14E). 
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Fig. 14. GSL comparative analysis in ESCs and EpiLCs. 
(A): Schematic diagram of the GSL synthetic pathway. (B): Absolute amount of GSL 
detected by MS. Galactosylceramide (GalCer), lactosylceramide (LacCer), globo (Gb), 
ganglio (Gg) and neolacto/lacto ((n)Lc). (C): Transcriptional analysis of GSL-specific 
enzymes normalized against Gapdh and shown as a fold change relative to ESCs. (D): 
GSL profiling by FACS using specific Abs. Ab specificities are stated below the labels and 
schematically represented above each histogram. The grey line at the bottom represents 
the negative control staining. (E): Model of GSL modifications during naïve to primed 
transition. Values are shown as means ± s.e.m. of three independent experiments (C), (D) 
and four independent experiments in (B). 
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Fig. 15. GSL MS spectra.  
Representative GSL MS spectra of ESCs and EpiLCs. To allow intensity comparison 
across ESCs and EpiLCs, MS signals in ESC and EpiLC spectra are scaled to the same 




Fig. 16. FACS profiling of GSL structures.  
Representative FACS histograms. Negative control: grey; ESC: black; EpiLC: blue. 
 



































No. deduced composition class 
1 (Hex)2 LacCer 
2 (Hex)3 Gb 
3 (Hex)4(HexNAc)2(2,6NeuAc)1 (n)Lc 
4 (Hex)5(HexNAc)3 (n)Lc 
5 (Hex)5(HexNAc)3(2,3Neu5Ac)1 (n)Lc 
6 (Hex)7(HexNAc)3 (n)Lc 
7 (Hex)6(HexNAc)3(2,3NeuAc)1 (n)Lc 
8 (Hex)2(2,3NeuAc)1 Gg 
9 (Hex)2(HexNAc)1(2,3NeuAc)1 Gg 
10 (Hex)2(2,3/2,3NeuAc)2 Gg 
11 (Hex)2(HexNAc)1(2,3/2,3NeuAc)2 Gg 
12 (Hex)2(2,3/2,3/2,3NeuAc)3 Gg 
13 (Hex)4(HexNAc)1 Gb/(n)Lc 
14 (Hex)3(HexNAc)2 Gb/(n)Lc 
15 (Hex)4(HexNAc)1(2,3NeuAc)1 Gb/(n)Lc 
16 (Hex)5(HexNAc)2 Gb/(n)Lc 
17 (Hex)4(HexNAc)3 Gb/(n)Lc 
18 (Hex)5(HexNAc)2(Fuc)1 Gb/(n)Lc 
19 (Hex)2(HexNAc)1 Gg/(n)Lc 
20 (Hex)2(HexNAc)2 Gg/(n)Lc 
21 (Hex)3(HexNAc)1(Fuc)1 Gg/(n)Lc 
22 (Hex)3(HexNAc)1(2,6NeuAc)1 Gg/(n)Lc 
23 (Hex)3(HexNAc)1(Fuc)1(2,3NeuAc)1 Gg/(n)Lc 
24 (Hex)3(HexNAc)1(2,3/2,3NeuAc)2 Gg/(n)Lc 
25 (Hex)3(HexNAc)1(2,3/2,6NeuAc)2 Gg/(n)Lc 
26 (Hex)3(HexNAc)1(2,3NeuAc)1(2,3NeuGc)1 Gg/(n)Lc 
27 (Hex)4(HexNAc)2(2,3NeuAc)1 Gg/(n)Lc 
28 (Hex)3(HexNAc)1(2,3/2,3/2,3NeuAc)3 Gg/(n)Lc 
29 (Hex)3(HexNAc)1 Gb/Gg/(n)Lc 
30 (Hex)3(HexNAc)1(2,3NeuAc)1 Gb/Gg/(n)Lc 
31 (Hex)4(HexNAc)1(Fuc)1 Gb/Gg/(n)Lc 
32 (Hex)3(HexNAc)1(2,3NeuGc)1 Gb/Gg/(n)Lc 
33 (Hex)4(HexNAc)2 Gb/Gg/(n)Lc 
34 (Hex)4(HexNAc)2(Fuc)1 Gb/Gg/(n)Lc 
35 (Hex)3(HexNAc)3 unknown 
36 (Hex)3(HexNAc)1(2,6/2,6NeuAc)2 unknown 
37 (Hex)4(HexNAc)1(Fuc)1(2,6NeuAc)1 unknown 
38 (Hex)3(HexNAc)2(Fuc)1(2,6NeuAc)1 unknown 
39 (Hex)6(HexNAc)3 unknown 
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3-2-5. Elongation/branching and capping/terminal modifications  
Glycosylation is a complex process involving more than 200 distinct glycosyltransferases 
and related enzymes in mammals. These can be classified as pathway-specific and 
pathway-non-specific, which generally include enzymes involved in biosynthetic steps 
overlapping different glycosylation classes (Fig. 17A). Real-time PCR analysis showed that 
B3galt1,2,5 and B4galt2-4, involved in type I chain (Galβ1-3GlcNAc) and type II chain 
(Galβ1-4GlcNAc) structures formation, respectively, were increased, whereas LacdiNAc 
(GlcNAcβ1-4GalNAc)-specific enzymes B4galnt3,4, which was previously reported to 
positively regulate LIF signaling in ESCs (Sasaki et al., 2011), were reduced in EpiLCs. 
Consistently with a higher level of KS (Fig. 11D), B4galt4, required for KS elongation 
(Lindahl et al., 2015-2017), was markedly increased. SSEA-3 upregulation observed by 
MS (Fig. 14D), correlated with a significantly higher expression of B3galt5, the enzyme 
involved in SSEA-3 synthesis on Gb (Schnaar and Kinoshita, 2015-2017) (Fig. 17B). An 
general enhancement of sialyltransferases, including St8sia2,4, the genes involved in 
polysialic acid (PSA) formation (Takashima and Tsuji, 2011), was observed in EpiLCs. 
St6gal1,2, the only sialyltransferases involved in N-glycans sialylation (Takashima and 
Tsuji, 2011), substantially increased in EpiLCs, demonstrating a correlation between the 
observed enhancement of α2,6 sialic acid structures on N-glycans by MS (Fig. 4B) and the 
enzyme expression. Fucosyltransferases expression strongly increased in EpiLCs, except 
for that of Fut9, the enzyme synthesizing SSEA-1 (Kudo et al., 2004). Remarkably, Fut1,2, 
involved in the formation of SSEA-5, showed a striking increase. Moreover, 
sulfotransferases mRNA levels were higher in EpiLCs. In particular, a significant increase 
in Chst2,4 (Fig. 17C), the sole sulfotransferases that catalyze the formation of extended or 
branched capped mucin-type O-glycan structure (Uchimura et al., 2005), confirming at the 
transcriptional level the data obtained by MECA-79 staining (Fig. 8D).  
To obtain further insights into the major pathway-non-specific structures, MS 
collected data were combined with a FACS profiling using a combination of different lectins 
and Abs. Structures characterized by MS and FACS strongly correlated with the 
expression of the relative enzymes. An increase in type II chain structures in EpiLCs, as 
indicated by erythrina corallodendron lectin (ECorL) staining was observed, despite Lewis 
x (Lex) type II structure (SSEA-1) was unchanged, likely because of decreased Fut9 
expression. Conversely, H1 antigen, a type I structure known as SSEA-5, was significantly 
enhanced in EpiLCs and only detected at a negligible level in ESCs. Overall fucosylation 
and sialylation levels were enhanced in EpiLCs, correlating with the observed increased 
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expression of the fucose and sialic acid nucleotide transporters (Fig. 18). Notably, sialic 
acid configuration shifted from an α2,6 to an α2,3 configuration in EpiLCs (Fig. 17D). 




(see legend in the next page) 
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Fig. 17. Pathway-non-specific comparative analysis in ESCs and EpiLCs. 
(A): Schematic diagram of major pathway-non-specific structures. The asterisk denotes 
enzyme putative activity. (B): Transcriptional analysis analysis of elongation/branching 
enzymes normalized against Gapdh and shown as a fold change relative to ESCs. (C): 
Transcriptional analysis of capping/terminal modification enzymes normalized against 
Gapdh and shown as a fold change relative to ESCs. (D): Total absolute amount of 
terminal modifications detected by MS (upper panel). Relative amount of total sialic acid in 
α2,3 and α2,6 configuration (lower panel). Fucose: Fuc; sialylation: Sia. (E): Pathway-non-
specific profiling by FACS using specific lectins/Abs. Lectin/Ab specificities are stated 
below the labels and schematically represented above each histogram. The grey line at 
the bottom represents the negative control staining. (F): Model of pathway-non-specific 
alterations during naïve to primed transition. Values are shown as means ± s.e.m. of three 
independent experiments in (B), (C), (E) and four independent experiments in (D).  
 
Fig. 18. NST transcriptional analysis in 
ESCs and EpiLCs. 
Transcriptional analysis analysis of NST 
normalized against Gapdh and shown as 
a fold change relative to ESCs. 
 
 




histograms. Negative control: 
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3-3. PRC2 regulates glycosylation alterations during ESCs to EpiLCs differentiation 
Since the glycome drastically changes during ESC differentiation to EpiLCs, we 
hypothesized the presence of a defined regulatory network. To identify putative 
candidates, an in-depth analysis of previously published chromatin immunoprecipitation 
sequencing (ChIP-seq) datasets obtained in ESCs using the ChIP-Atlas comprehensive 
database was performed (Oki et al., 2018) (https://chip-atlas.org). As a result, PRC2 
components were observed to occupy a great variety of glycosylation-related genes 
across all glycosylation classes in ESCs (Fig. 20A; Fig. 21). PRC2, whose core 
components are Suz12, Eed, and either Ezh2 or Ezh1, is a chromatin-remodeling complex 
which catalyzes the H3K27me3 modification to promote gene repression. PRC2 can 
associate with other factors that regulate its chromatin recruitment, such as Mtf2 or Jarid2, 
to form two different subtypes of PRC2 named PRC2.1 and PRC2.2, respectively. In 
addition, PRC2 can synergically repress gene expression together with PRC1, which is 
composed by core components, such as Rnf2 (Deevy and Bracken, 2019, Gökbuget and 
Blellock, 2019). Further analysis of ChIP-seq data indicated that PRC2.1, PRC2.2 and 
Rnf2 (PRC1) act cooperatively to regulate around 27% of the glycosylation-related genes 
in ESCs (Fig. 20B), suggesting that PRC2 is involved in glycosylation changes occurring 
during ESC differentiation to EpiLCs. To test this hypothesis, ESCs were treated with the 
PRC2 inhibitor EED226 (Qi et al., 2017) and examined the effects on the glycome. 
EED226 treatment resulted in a significant reduction of the H3K27me3 modification (Fig. 
20C,D). Next, we compared the glycosylation alterations observed by FACS during the 
ESC differentiation to EpiLCs and in ESCs after EED226 treatment. Strikingly, many 
structures were increased or decreased both in EpiLCs and EED226-treated ESCs, 
indicating a direct modulation by PRC2 (red in Fig. 20E). Conversely, other structures 
showed an opposite trend in EpiLCs and EED226-treated ESCs, suggesting the presence 
of other regulatory component(s) (blue in Fig. 20E). Finally, some structures were altered 
in EpiLCs but unchanged in EED226-treated ESCs, implying the presence of PRC2-
independent pathway(s) (black in Fig. 20E). Transcriptional analysis of PRC2 core 
components by RNA-seq in ESCs and EpiLCs showed a decrease at the transcriptional 
level of the PRC2 core component Eed (Fig. 20F). Moreover, global H3K27me3 has been 
previously reported to be drastically reduced and redistributed upon ESC differentiation to 
EpiLCs (Kurimoto et al., 2015), providing further evidence supporting our PRC2-mediated 
glycosylation regulatory network model during the naïve to primed transition. To further 
confirm that PRC2 is involved in glycan changes during the ESC to EpiLC transition we 
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examined the glycosyltransferase and related enzyme expression difference in ESCs vs 
EpiLCs and EED226 untreated vs EED226 treated samples by RNA-seq. Similar to the 
changes observed at the structural level, we observed three different patterns of 
expression: expression increased or decreased both in EpiLCs and EED226- treated 
ESCs (43% of the glycosyltransferases and related genes); or following an opposite trends 
of expression (22% of the glycosyltransferases and related genes); or unaffected by PRC2 
treatment and changed during the naïve-to-primed transition (29% of the 
glycosyltransferases and related genes) (Fig. 20G). Collectively, these data indicate the 
presence of at least three coordinated pathways that control glycosylation dynamics during 
EpiLC differentiation (Fig. 20H). In conclusion, these findings demonstrate for the first time 
that PRC2 mediates the glycosylation dynamics during the naïve to primed pluripotency 
state transition (Fig. 22). 
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(see legend in the next page) 
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Fig. 20. PRC2 mediates glycosylation dynamics during ESC to EpiLC transition. 
(A): Previously published ChIP-seq datasets obtained from wild-type/untreated ESCs 
precipitated: anti-Suz12 Ab (SRX1372665) (Kloet et al., 2016), anti-Ezh2 Ab 
(SRX2528911) (Perino et al., 2018), anti-Mtf2 Ab (SRX2776968) (Li et al., 2017), anti-
Jarid2 Ab (SRX3738839) (Perino et al., 2018) and anti-Rnf2 Ab (SRX191072) (He et al., 
2013). Percentages of ChIP occupancy per glycosylation class were determined within a 
range of ± 5kb and with a threshold for statistical significance set as 50 (1 < 1E-05) 
calculated by peak-caller MACS2. (B): Venn diagrams showing the ChIP occupancies of 
PRC components overlap on glycosylation genes. (C): FACS analysis of H3  
and H3K27me3 after EED226 treatment for 48h and relative fluorescence mean intensity 
shown as a fold change relative to that of DMSO-treated cells. Negative control: grey; 
DMSO: black; EED226: blue. (D): Representative image of a western blot of H3K27me3, 
H3 and Gapdh in EED226-treated ESCs. (E): FACS profiling using specific lectins/Abs in 
EpiLCs and EED226-treated ESCs, and shown as a fold change relative to ESCs and 
DMSO-treated ESCs (control), respectively. Lectin/Ab specificities are schematically 
represented above each histogram. The dotted line indicates the control. (F): Heat map of 
PRC2 core components, PRC2.1 and PRC2.2 main accessory subunits detected in ESCs 
and EpiLCs by RNA-seq. (G): Pie charts showing percentage of glycosylation related 
genes in each expression pattern by comparing ESCs/EpiLCs and EED226 
untreated/EED226 treated samples expression by RNA-seq. Genes following a similar 
expression pattern during EpiLC differentiation and EED226 treatment (red), opposite 
patterns (blue), and changed in EpiLCs but not upon EED226 treatment (black) (the grey 
label indicates genes which expression was unchanged). RNA-seq data were obtained 
from a single experiment. (H): Schematic model of the glycosylation regulatory network 
during ESC to EpiLC transition: PRC2 direct regulation (1, red), PRC2 regulation together 
with other unidentified factor(s) (2, blue), and PRC2-independent pathway(s) (3, black) 
(the grey label indicates unchanged structures). Values are shown as means ± s.e.m. of 
three independent experiments.  
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Fig. 21. PRC binding to 
glycosyltransferases 
genes.  
PRC components binding to 
each glycosyltransferase 
gene. ChIP-seq datasets 
relative to Fig. 20. 
 
Fig. 22. Schematic model of glycosylation dynamics during ESC to EpiLC transition.  
Glycome undergoes dramatic alterations during the naïve to primed transition and these 
changes are partially mediated by PRC2. The size of each pie chart reflects the absolute 
mean quantity of glycans (pmol/100 μg of protein). N-linked and GSL pie charts size is 
scaled 2 and 20 times, respectively.  
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3-4. C1galt1 is the most abundant pathway in ESC and during early differentiation 
Next, mucin-type O-glycosylation role in ESC pluripotency network was explored. Mucin-
type O-glycosylation is characterized by the initial addition of GalNAc to a serine or 
threonine residues of the target protein by a family of 19 transferases (Galnts) in mouse to 
form the so-called Tn antigen. Tn antigen is further elongated by St6galnac1, C1galt1, or 
B3gnt6 to synthesize sTn antigen, T antigen (Core 1), or Core 3 structure, respectively 
(Fig. 23A). The partial functional redundancy of Galnts makes analysis of their function 
highly complex (Bennet et al., 2012); we therefore focused on the catalyzation step 
following Tn antigen formation that is selectively performed by St6galnac1, C1galt1, or 
B3gnt6. In addition to sTn antigen, T antigen, and Core 3 structure, the Tn antigen can 
also be extended to form Core 5 to 8 structures. However, Core 5 to 8 structures have an 
extremely restricted occurrence and the glycosyltransferases involved in their formation 
remain to be fully characterized (Brockhausen et al., 2009); thus, they have not been 
considered in the present study. 
Total RNA expression analysis in ESCs showed that C1galt1 was the most highly 
expressed among the three enzymes (Fig. 23B). MS analysis of O-glycans in ESCs 
identified T antigen, and its further modifications, as the only detectable structures among 
sTn antigen, T antigen, and Core 3 structure (Fig. 23C). Notably, the absolute amount of T 
antigen, and C1galt1-mediated elongation pathway modifications, were consistent among 
different ESC lines, suggesting that the C1galt1 elongation pathway plays a crucial role in 
ESCs (Fig. 24A,B). Investigation of the O-glycosyltransferase dynamics during early and 
late differentiation by using an embryoid body (EB) assay was carried out. C1galt1 showed 
the highest level of expression among the three O-glycosyltransferases between day 0 
and day 4, suggesting that the C1galt1-mediated elongation pathway have a role during 
early differentiation of ESCs. However, at later differentiation stages, expression of all 
three enzymes increased dramatically, indicating that ESC cells surface is decorated by 
several types of O-glycan structure at late differentiation stages (Fig. 24C-E).  
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Fig. 23. C1galt1 elongation pathways is the most abundant pathway in ESCs.  
(A): Schematic diagram of mucin-type O-glycosylation pathway initial step. (B): Genes 
absolute quantification by real-time PCR. The genes copy number is normalized to that of 
Gapdh. The values are shown as means ± s.e.m. of three independent experiments. (C): 
Absolute amount of O-glycan structures detected by MS. sTn antigen (sTn), Core 3 
structure (Core 3), T antigen, and C1galt1-mediated elongation pathway modifications; sT 
antigen (sT), disialyl T antigen (di-sT), and extended T antigen or Core 2 structure (Ex T or 
Core 2). The data were obtained from a single technical and biological replicate. N.D. not 
detected. 
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Fig. 24. C1galt1 elongation pathways is the most abundant pathway during early 
differentiation.  
(A): Relative and absolute amount of sTn antigen (sTn), T antigen, and Core 3 structure 
(Core 3) by MS in R1 (white box) and E14TG2a cell lines (black box). (B): Relative and 
absolute amount of O-glycan structures detected by MS in R1 and E14TG2a cell lines. T 
antigen (black box), and C1galt1-mediated elongation pathway modifications; sT antigen 
(sT, red box), disialyl T antigen (di-sT, dark blue box), and extended T antigen or Core 2 
structure (Ex T or Core 2, light blue box). The data were obtained from a single technical 
and biological replicate. N.D. not detected. (C), (D): Transcriptional analysis of genes in 
embryoid bodies (EB) at day 0 (ESC), 2.5, 4, 8, and 12 normalized against Gapdh. (E): 
St6galnac1, C1galt1, B3gnt6, and Gapdh mRNA quantification by PCR. mRNA was 
amplified by PCR using 25 cycles to avoid saturation and separated on polyacrylamide 
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3-5. C1galt1 knockdown results in ESCs differentiation via canonical Wnt signaling 
To clarify the role of the C1galt1 elongation pathway, we performed a RNAi knockdown 
(KD) of C1galt1. At 4 days after transfection, C1galt1 KD cells showed reduced C1galt1 
expression (Fig. 25A) followed by a decrease of T antigen at the surface and internally as 
shown by PNA staining (Fig. 25B-F). C1galt1 KD resulted in a drastic increase in Tn 
antigen and a mild decrease in sTn antigen at the cell surface (Fig. 26A-D). C1galt1 KD 
cells exhibited a flat shape, which is typical of differentiated cells, compared to the dome-
shape morphology of undifferentiated cells (Fig. 27A). Next, we analyzed the expression of 
the core pluripotency markers Oct3/4 and Sox2 and of SSEA-1, a pluripotent cell surface 
marker (Nakai-Futatsugi and Niwa, 2013). The expression of Oct3/4 and Sox2 was 
significantly decreased in C1galt1 KD cells compared to the control; a similar decrease at 
the protein level was also observed (Fig. 27B-D). The SSEA-1+ cell population was 
reduced in C1galt1 KD cells compared to the control (Fig. 27E). To assess the ability of 
C1galt1 KD cells to self-renew we performed an alkaline phosphatase (ALP) assay 4 days 
post transfection. The number of ALP positive colonies was markedly decreased in 
C1galt1 KD cells, demonstrating that the self-renewing ability of C1galt1 KD cells was 
compromised (Fig. 27F). ESC pluripotency and self-renewal loss following C1galt1 KD 
was further confirmed by using stable C1galt1 KD ESCs (Fig. 28A-D). C1galt1 KD resulted 
in an upregulation of the trophoblast markers Cdx2 and Gata3, suggesting that C1galt1 KD 
induces ESC transdifferentiation toward the trophectoderm (Fig. 27G). Consistently, an EB 
assay showed an enhanced differentiation potential in C1galt1 KD ESCs (Fig. 28E,F). 
These findings demonstrate that C1galt1 KD cells spontaneously exit from pluripotency, 
even in the presence of LIF. 
Previous studies reported that mucins, which are heavily O-glycosylated proteins, interact 
with β-catenin, the key mediator of the canonical Wnt signaling, in many tumors (Pai et al., 
2016). Therefore, we hypothesized that C1galt1 KD might alter canonical Wnt signaling in 
ESCs. Activation of Wnt signaling results in inhibition of β-catenin phosphorylation, thereby 
preventing its degradation. Stabilized β-catenin accumulates in the cytoplasm and 
translocates to the nucleus where, together with Tcf/Lef, it triggers Wnt specific target 
genes transcription (Nusse and Clevers, 2017). C1galt1 KD cells exhibited a reduction in 
phospho-β-catenin (p-β-catenin) and an increase in total β-catenin (Fig. 29A,B). β-catenin 
expression was reduced, indicating that C1galt1 KD resulted in increased β-catenin protein 
stability (Fig. 29C). A luciferase assay using a β-catenin/Tcf responsive element (TOP) 
showed a marked increase of Wnt signaling (Fig. 29D), followed by an increased 
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expression of the Wnt specific target gene Axin2 (Fig. 29E). Moreover, immunostaining of 
β-catenin in permeabilized C1galt1 KD cells showed an increased localization of β-catenin 
in the nucleus compared to the control (Fig. 29F,G), demonstrating that C1galt1 KD 
promotes canonical Wnt signaling activation in ESCs. Mucins have also been reported to 
activate PI3K/Akt and Fgf signaling in breast cancer cells (Woo et al, 2012; Hiraki et al, 
2016). However, C1galt1 KD did not result in activation of PI3K/Akt and Fgf signaling 
pathways in ESCs (Fig. 30A-D).  
 
 
Fig. 25. C1galt1 KD results in T antigen reduction.  
(A): Transcriptional analysis of C1galt1 KD cells normalized against the amount of β-actin. 
(B): FACS staining by PNA of C1galt1 KD. (C): Fluorescence mean intensity of image (B). 
The fold change is relative to that of control cells. (D): Representative image of cell 
surfaces of C1galt1 KD cells after immunostaining using PNA. Nuclei were stained with 
Hoechst. Scale bar, 10 μm. (E): Representative image of a maximum intensity projection 
of internal molecules in C1galt1 KD cells after immunostaining using PNA. Nuclei were 
stained with Hoechst. Scale bar, 10 μm. (F): PNA mean intensity in image (E). The mean 
intensity is shown as fold change relative to that of the control. The values are shown as 
means ± s.e.m. of three independent experiments.  
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Fig. 26. C1galt1 KD results in Tn antigen increase.   
(A): FACS staining by HPA in C1galt1 KD cells. (B): Fluorescence mean intensity of 
image (A). (C): FACS staining by SNA in C1galt1 KD cells. (D): Fluorescence mean 
intensity of image (C). The fold change is relative to that of control cells. The values are 
shown as means ± s.e.m. of three independent experiments.  
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Fig. 27. C1galt1 transient KD results in exit from the pluripotent state.   
(A): C1galt1 KD ESCs morphology. Scale bar, 200 μm. (B): Transcriptional analysis of the 
pluripotent markers in C1galt1 KD cells normalized against β-actin. (C): Representative 
image of a western blot analysis of pluripotent markers in C1galt1 KD cells. (D): Oct3/4 
and Sox2 in image (C) were normalized to β-actin. (E): Density plot by FACS of C1galt1 
KD cells stained with anti-SSEA-1 Ab and PNA. The dark line separates the SSEA-1+ 
population and the SSEA-1- population. (F): ALP assay of C1galt1 KD cells. Scale bar, 25 
μm. (G): Transcriptional analysis of differentiation markers in C1galt1 KD cells normalized 
against β-actin and shown as a fold change relative to control cells. The values are shown 
as means ± s.e.m. from three or five ((C) and (D)) independent experiments.  
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Fig. 28. C1galt1 stable KD results in exit from the pluripotent state.   
(A): Transcriptional analysis of the pluripotent markers in C1galt1 KD cells normalized 
against β-actin. (B): Density plot by FACS of C1galt1 KD cells stained with anti-SSEA-1 
Ab and PNA. The dark line separates the SSEA-1+ population and the SSEA-1- population. 
(C): PNA and SSEA-1 fluorescence mean intensity of image (B). (D): ALP assay of stable 
C1galt1 KD cells. Scale bar, 25 μm. (E), (F): Transcriptional analysis of C1galt1 in 
embryoid bodies (EB) from transient C1galt1 KD ESCs plated 2 days post transfection and 
collected at day 0 (ESC), 2, 3, and 4 normalized to Gapdh. The values are shown as 
means ± s.e.m. of three independent experiments. 
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Fig. 29. C1galt1 KD results in Wnt signaling activation.   
(A): Representative image of western blot analysis using p-β-catenin Ab and β-catenin Ab 
in C1galt1 KD cells. (B): β-catenin and p-β-catenin western blot normalized against β-actin 
and β-catenin, respectively. (C): Transcriptional analysis of β-catenin in C1galt1 KD cells 
normalized against β-actin. (D): β-catenin reporter assay of C1galt1 KD cells. The relative 
light unit amount is shown as a ratio of TOPFLASH/FOPFLASH normalized against β-
galactosidase. (E): Axin2 expression in C1galt1 KD cells normalized against β-actin. (F): 
Representative image of intracellular molecules using PNA and an anti-β-catenin Ab in 
C1galt1 KD cells. Nuclei were stained with Hoechst. Scale bar, 10 μm. (G): Cytoplasmic 
and nuclear β-catenin mean intensity of C1galt1 KD cells. The values are shown as means 
± s.e.m. of three independent experiments. 
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Fig. 30. C1galt1 KD do not affect FGF and Akt signaling.   
(A): Representative image of western blot analysis using p-Erk1/2 Ab and Erk1/2 Ab in 
C1galt1 KD cells. (B): p-Erk1/2 western blot band normalized against Erk1/2. (C): 
Representative image of western blot analysis using p-Akt Ab and Akt Ab in C1galt1 KD 
cells. (D): p-Akt western blot normalized against Akt. The values are shown as means ± 
s.e.m. of three independent experiments; n.s. not significant. 
 
3-6. Frizzled-5 endocytosis is mediated by Galectin-3 binding to T antigen 
Canonical Wnt signaling is initiated by the binding of the Wnt ligand to its receptor Fzd, 
which in turn dimerizes with the co-receptor LRP5/6 and results in downstream signaling 
(Nusse and Clevers, 2017). Among the Fzd receptor family involved in the canonical Wnt 
signaling Fzd5 is the most highly expressed in ESCs and plays an essential role during 
development (Hao et al., 2006). A pull-down assay using biotinylated PNA showed that 
Fzd5 was successfully precipitated, demonstrating that Fzd5 carries T antigen (Fig. 31A). 
Immunoprecipitation on an ESC lysate using an anti-Fzd5 antibody (Ab) followed by a 
lectin blot analysis using PNA confirmed that Fzd5 was modified by T antigen (Fig. 31B). 
Moreover, the amount of Fzd5 protein precipitated in C1galt1 KD cells decreased 
compared to the control, further confirming that Fzd5 is O-glycosylated (Fig. 31C,D). 
Notably, T antigen was not detected by lectin blot analysis for LRP5 and LRP6 
immunoprecipitates (Fig. 32). Collectively, these data demonstrate for the first time that 
Wnt receptor Fzd5 carries T antigen.  
Mucin-type O-glycosylation has multiple functions, such as in protein-protein interaction, 
and in trafficking and turnover of cell surface proteins (Razawi et al., 2013; Karabasheva et 
al., 2014). Immunostaining using an anti-Fzd5 Ab in permeabilized C1galt1 KD cells 
showed a striking reduction of internalized Fzd5 (Fig. 33A-C). In contrast, Fzd5 staining at 
the cell surface increased in C1galt1 KD cells (Fig. 33D). A surface biotinylation assay 
demonstrate that Fzd5 was strikingly increased on the surface of C1galt1 KD cells (Fig. 
33E). Furthermore, ultrastructural localization of Fzd5 by immunoelectron microscopy 
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showed that colloidal gold labeling was scarcely present on the plasma membrane of 
control cells compared to C1galt1 KD cells (Fig. 33F), further confirming that Fzd5 was 
retained at the cell membrane after C1galt1 KD. Upon ESCs treatment with the O-
glycosylation inhibitor benzyl 2-acetoamido-2-deoxy-α-D-galactopyranoside (GalNAc-Bn), 
a similar effect to that in C1galt1 KD cells was observed (Fig. 34A-D), confirming that T 
antigen on Fzd5 is involved in its internalization. The ultrastructural localization of Fzd5 
was investigated using two different Abs against Fzd5. Colloidal gold labeling was 
observed inside and outside the endosomes of control cells using anti-Fzd5 Abs against 
the N-terminal and C-terminal regions, respectively (Fig. 33G). In addition, immunostaining 
showed that the early endosome marker Rab5 colocalized with Fzd5 in ESCs (Fig. 33H), 
demonstrating that Fzd5 is cleared from the plasma membrane by endocytosis.  
Galectins (Lgals) belong to a family of proteins that bind to β-galactose (Johannes 
et al., 2018). Previous studies reported that Lgals, in particular Lgals3, promote 
endocytosis (Merlin et al., 2011; Gao et al., 2012; Lepur et al., 2012; Lakshminarayan et 
al., 2014). Furthermore, frontal affinity chromatography analysis demonstrated that T 
antigen is a ligand for Lgals9, followed by Lgals2, Lgals3, and Lgals4 (Iwaki and 
Hirabayashi, 2018). Thus, we hypothesized that Lgals are involved in Fzd5 endocytosis. 
Immunostaining in permeabilized ESCs showed a marked reduction of internalized Fzd5 in 
ESCs treated with a high concentration of lactose, demonstrating that Lgals regulate Fzd5 
endocytosis (Fig. 35A,B). RNA-seq analysis showed that Lgals3 was the most highly 
expressed in ESCs (Fig. 35C). Consistently, addition of Lgals3 resulted in an increase of 
internalized Fzd5, confirming that Lgals3 is involved in Fzd5 endocytosis in ESCs (Fig. 
35D,E). In conclusion, our findings demonstrate that reduction of T antigen results in 
disruption of Lgals3-mediated endocytosis of the Wnt receptor Fzd5. As a result, Fzd5 is 
retained at the plasma membrane, thereby prolonging the activation of Wnt signaling and 
culminating in ESCs exit from pluripotency (Fig. 36).  
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Fig. 31. Wnt receptor Frizzled-5 carries T antigen. 
(A): Representative image of a western blot (IB) using an anti-Fzd5 Ab on the lectin 
precipitated fraction (LP) precipitated with biotinylated PNA. The input represents the total 
ESC lysate. Similar results were obtained in four independent experiments. (B): 
Representative image of a western blot (IB) using an anti-Fzd5 Ab and lectin blot (LB) by 
PNA-HRP on the immunoprecipitated fraction (IP) precipitated with an antibody against 
Fzd5. The input represents the total ESC lysate. The arrowhead indicates Fzd5. Similar 
results were obtained in three independent experiments. (C): Representative image of a 
western blot (IB) using an anti-Fzd5 Ab on the lectin precipitated fraction precipitated with 
biotinylated PNA in C1galt1 KD cells. Similar results were obtained in three independent 
experiments. (D): Representative image of western blot using an anti-Fzd5 Ab in C1galt1 
KD cells. Similar results were obtained in three independent experiments.  
 
Fig. 32. LRP5/6 are not mucin-type O-glycosylated. 
Representative images of western blot (IB) using an anti-LRP5 
Ab (upper panel), or an anti-LRP6 Ab (lower panel), and lectin 
blot (LB) using PNA, on the immunoprecipitated fraction (IP) 
precipitated with an antibody against LRP5 (upper panel), or 
LRP6 (lower panel). The input represents the total ESC lysate. 
Similar results were obtained from three independent 
experiments. 
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Fig. 33. T antigen regulates Frizzled-5 endocytosis. 
(A): Representative image of a maximum intensity projection of intracellular molecules 
using PNA and an anti-Fzd5 Ab in C1galt1 KD cells. Nuclei were stained with Hoechst. 
Arrowheads indicate Fzd5 puncta staining. Scale bar, 10 μm. (B): 3D reconstruction of 
images in (A) using Imaris version 9.3.1. Scale bar, 10 μm. (C): Quantification of Fzd5 
puncta staining normalized against the number of nuclei. (D): Magnification of areas 
highlighted in image (A). Scale bar, 2.5 μm. (E): Fzd5 surface protein in C1galt1 KD cells 
using a surface biotinylation assay. (F): Representative transmission electron micrographs 
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from C1galt1 KD cells. Arrowheads indicate Fzd5 staining at the plasma membrane. Scale 
bar, 500 nm. The micrographs were obtained from a single biological replicate. (G): 
Representative transmission electron micrographs from control cells showing the 
ultrastructural localization of Fzd5 in the endosome. Colloidal gold labeling is inside the 
endosome using an anti-Fzd5 Ab against the N-terminal region (upper panel), and outside 
the endosome using an anti-Fzd5 Ab against the C-terminal region (lower panel). Scale 
bar, 10 nm. The micrographs were obtained from a single biological replicate. (H): 
Representative image of a maximum intensity projection of intracellular molecules using 
an anti-Fzd5 Ab and an anti-Rab5 Ab in ESCs. Arrowheads indicate colocalization of Fzd5 
puncta and Rab5. Scale bar, 10 μm. Values are shown as means ± s.e.m. of three 
independent experiments.  
 
 
Fig. 34. Mucin-type O-glycosylation inhibitor reduces Frizzled-5 internalization. 
(A): Representative image of a maximum intensity projection of intracellular molecules 
using PNA and an anti-Fzd5 Ab in the presence or absence of 2 mM GalNAc-Bn for 48 hr. 
Nuclei were stained with Hoechst. Arrowheads indicate Fzd5 puncta staining. Scale bar, 
10 μm. (B): 3D reconstruction of images in (A) using Imaris version 9.3.1. Scale bar, 10 
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μm. (C): Quantification of Fzd5 puncta staining normalized against the number of nuclei 
and shown as a fold change relative to control. (D): Magnification of highlighted areas in 




Fig. 35. Frizzled-5 endocytosis is mediated by galectin-3 binding to T antigen. 
(A): Representative image of a maximum intensity projection of intracellular molecules 
using an anti-Fzd5 Ab and an anti-Lgals3 Ab in ESCs treated with 50 mM lactose 
monohydrate. Arrowheads indicate colocalization of Fzd5 puncta and Lgals3. Scale bar, 
10 μm. (B): Quantification of Fzd5 puncta staining of image (A) normalized against the 
number of nuclei. (C): Galectins expression in ESCs analyzed by RNA-seq. RNA-seq data 
obtained from a single technical and biological replicate. (D): Representative image of a 
maximum intensity projection of intracellular molecules using an anti-Fzd5 Ab and an anti-
Lgals3 Ab in ESCs treated with 15 μg/mL of recombinant Lgals3. Arrowheads indicate 
colocalization of Fzd5 puncta and Lgals3. Scale bar, 10 μm. (E): Quantification of Fzd5 
puncta staining of image (D) normalized against the number of nuclei. Values are shown 
as means ± s.e.m. of three independent experiments.  
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Fig. 36. Schematic representation of ESC pluripotency regulation by mucin-type O-
glycosylation. 
Mucin-type O-glycosylated Wnt receptor Frizzled-5 on wild-type (WT) ESCs is cleared 
from the plasma membrane by endocytosis via the binding of galectin-3 to T antigen, 
resulting in β-catenin constitutive signaling which promotes the maintenance of ESC 
pluripotency. By contrast, C1galt1 KD ESCs show disrupted galectin-3 mediated 
endocytosis of Frizzled-5 and its retention at the plasma membrane. As a result, Wnt 
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4. Discussion 
The pivotal role of glycosylation during development and in determining stem cell identity 
across different species is becoming increasingly clear (Nishihara, 2018). Previous studies 
reported the glycomic profiles of mouse and conventional human ESCs, hiPSCs, tumors 
and late differentiating cells (Nairn et al., 2012; Fujitani et al., 2013; Homan et al., 2019). In 
the present study, a comparative and comprehensive analysis to investigate the 
glycosylation dynamics during the pluripotency state transition from ESCs to EpiLCs was 
performed. As a result, we demonstrate that glycosylation undergoes dramatic alterations 
from early stages of development, and we identified PRC2 as a key component involved in 
these changes (Fig. 22).  
PSCs in the primed state exhibit substantial differences compared to their naïve 
counterpart, such as a flat morphology, glycolytic metabolism, slow proliferation, and 
closer chromatin (Weinberger et al, 2016). During the pluripotency state transition, RAS 
mediates the epithelial-to-mesenchymal transition (EMT), characterized by the switch from 
epithelial cadherin (Ecad) to neural cadherin (Ncad) (Altshuler et al, 2018); a process 
similar to cancer progression and tightly regulated by glycosylation (Pinho et al, 2011; 
Pinho and Reis, 2015). In fact, it has been reported that N-glycosylation 1-6 branching 
structure on Ecad promotes its clearance from the cell surface and inhibits Ncad-mediated 
cell-cell adhesion. Furthermore, core fucosylation weakens Ecad cell-cell adhesion in lung 
cancer (Pinho et al, 2011). Moreover, an increased amount of sialylated glycans (Pinho 
and Reis, 2015) and reduced GSL (Guan et al, 2009) were documented to correlate with 
EMT progression. Similarly, we detected enhanced 2,6 branching, core fucosylation (Fig. 
4B,E), and total sialylated glycans (Fig. 17D), followed by a sharp reduction in GSL (Fig. 
14B), indicating a common EMT regulation by glycosylation across different biological 
contexts. RAS activation was also reported to be linked to a metabolic shift from oxidative 
phosphorylation to glycolysis, and subsequent closer chromatin during the naïve-to-primed 
transition (Altshuler et al, 2018). Notably, RAS is downstream of FGF signaling, which 
requires N-sulfation of HS. Moreover, Myc amount, which controls the ESCs’ proliferative 
program thus regulating the proliferation speed, is inversely correlated with FGF-ERK 
activation (Díaz-Díaz et al, 2017), highlighting the functional importance of FGF signaling 
regulation by HS. Accordingly, we observed a substantial increase in Ndst2-4 expression 
and N-sulfated HS staining (Fig. 11C,D). Our data emphasize that glycosylation dynamic 
changes contribute and partially drive the major phenotypical alterations occurring during 
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the pluripotency state transition, thus underlining the importance of functionally dissecting 
the role of glycosylation during developmental transitions in vitro and in vivo.   
Comprehensive analysis of total glycomes allows the identification of pluripotency 
biomarker candidates (Fujitani et al., 2013). Indeed, our data confirmed previously 
established pluripotency markers, such as SSEA-1,3,4 and Forsmann antigen, which are 
expressed at a similar level in the naïve and primed state. Moreover, we demonstrated 
that SSEA-5 is specifically expressed in EpiLCs, augmenting previous studies performed 
in conventional hESCs and hiPSCs (Tang et al., 2011). In addition, we identified a wide 
range of novel structures across all glycosylation classes that are specifically enhanced in 
the primed state but not detected or detected at very low levels in the naïve state, 
providing additional markers to distinguish between the different pluripotent states: 
bisecting GlcNAc and 2,6 branched tri-/tetra-antennary complex N-glycans, extended or 
branched capped mucin-type O-glycan structure, N-unsubstituted GlcN, N-sulfated GlcN, 
and 3-O-sulfated HS, CS-A, C, D and E units, and PSA.  
The recent establishment of culture conditions to reprogram mouse ESCs into 
expanded potential stem cells (EPSCs) or 2-cell-embryo-like cells (2CLCs) allowed the in 
vitro investigation of the totipotent state. Despite the most suitable in vitro system to model 
the totipotent state is still under debate (Posfai et al., 2020 preprint), these models allowed 
the identification of some molecular features of totipotent cells (Yang et al., 2017; 
Hendrickson et al., 2017; Posfai et al., 2020 preprint), providing an invaluable tool to 
characterize the totipotent state. It will be of great interest to examine the glycosylation 
dynamics during the reprogramming process from ESCs to EPSCs and 2CLCs to establish 
novel totipotency biomarkers and obtain mechanistic insights into the transition from the 
totipotent to the pluripotent state. 
PRC2 regulates early embryonic specification processes by repressing crucial 
developmental genes (Boyer et al., 2006). Indeed, deficiency in PRC2 core components 
Eed, Suz12, or Ezh2 results in embryo lethality around E7.5-E8.5 due to gastrulation 
defects (Deevy and Bracken, 2019). Here, we showed for the first time that PRC2 
contributes to overall glycosylation alterations occurring during the naïve to primed 
transition. Recently, ISY1 has been reported to modulate the biogenesis of a large subset 
of crucial miRNAs during the transition from ESCs to EpiLCs (Du et al., 2018). Moreover, 
PRC2 represses around 512 developmental regulators in ESCs (Boyer et al., 2006). Thus, 
the glycosylation changes we observed in EpiLCs are likely to be the result of the synergic 
action of PRC2 on glycosylation-related genes expression together with other 
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component(s) involved both directly and indirectly in the glycosylation pathway and PRC2-
independent pathway(s). In addition, PRC1 and PRC2 activity is directly modulated by O-
GlcNAc (Decourcelle et al., 2019), suggesting a metabolically regulated network 
controlling the glycomic profile.   
Glycosylation is a developmentally coordinated post-translational modification 
(Haltiwanger and Lowe, 2004; Nishihara, 2018). Previous studies have identified 
glycosylation class-specific key regulators. For example, hepatocyte nuclear factor 1α 
(HNF1α) was shown to control N-glycan fucosylation of human plasma proteins (Lauc et 
al., 2010). More recently, autism susceptibility candidate 2 (Auts2) was found to drive GSL 
metabolic switch during neural differentiation from mouse ESCs (Russo et al., 2018). 
Nonetheless, regulation of overall glycosylation dynamics has remained unknown. Here, 
PRC2 was shown to contribute to the glycosylation changes occurring during naïve to 
primed transition, demonstrating that the glycome complex alterations occurring during 
developmental transitions are orchestrated by a defined regulatory network. Consequently, 
it will be important to characterize the glycomic dynamics in a variety of developmental 
stages and cell types in order to identify transition-specific glycosylation regulatory 
components.  
It is becoming clear that glycosylation acts as a pivotal regulatory switch of 
pluripotency in a range of cell types in different organisms (Nishihara, 2018). In the present 
study, the function of mucin-type O-glycosylation in the pluripotency network and the 
relationship between O-glycosylation and signaling in ESCs was characterized. In brief, 
C1galt1 knockdown results in a decrease of T antigen on the Wnt receptor Fzd5, reducing 
the level of Lgals3-mediated Fzd5 endocytosis. The retention of Fzd5 on the surface, in 
turn, promotes excessive canonical Wnt signaling activation via β-catenin stabilization, 
resulting in the exit from pluripotency (Fig. 36).  
A recent study showed that mucin-type O-glycosylation plays a critical role in 
maintaining the epithelial state of trophoblast stem cells, which are derived from the first 
embryo lineage commitment (Raghu et al., 2019). Furthermore, C1galt1 KD induced 
expression of the trophectoderm markers Cdx2 and Gata3 (Fig. 27G). Thus, it will be of 
particular interest to investigate the role of mucin-type O-glycosylation in the early 
commitment of ESCs and in early embryo development in vivo.  
In the past decade, Wnt signaling has been shown to be a key factor in the 
maintenance of the undifferentiated state. The addition of Wnt3a and LIF is sufficient to 
support self-renewal and allows derivation of ESCs from non-permissive strains (ten Berge 
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et al., 2011). The induction of Wnt signaling by CHIR together with the FGF signaling 
inhibitor PD is commonly used to maintain the undifferentiated state in cultured ESCs 
(Ying et al., 2008; Ying and Smith, 2017). However, Wnt signaling outcome depends on its 
interactions with other signaling pathways. CHIR alone induces ESC differentiation (Ying 
et al., 2008). In addition, other groups have reported that β-catenin promotes the 
expression of genes associated with both pluripotency and differentiation (Kelly et al., 
2011; Price et al., 2013; Zhang et al., 2013). Therefore, Wnt signaling maintains the 
undifferentiated state while at the same time priming cells for differentiation. Here, Wnt 
signaling dysregulation led to a loss of ESC pluripotency.  
Mucin-type O-glycosylation plays multiple roles: protection from shedding; protein-
protein interactions; and, protein turnover and trafficking (Tian and Ten Hagen, 2009; 
Razawi et al., 2013; Karabasheva et al., 2014). In this study, T antigen on the Wnt 
receptor Fzd5 was found to modulate endocytosis of Fzd5 via Lgals3 (Fig. 36). Fzd 
endocytosis modulates Wnt signaling positively or negatively depending on the cellular 
context (Brunt and Scholpp, 2018). Here, a reduction in Fzd5 endocytosis resulted in Wnt 
signaling activation. Abnormalities in mucin-type O-glycosylation and Wnt signaling are 
hallmarks of tumorigenesis (Pinho and Reis, 2015; Zhan et al., 2017). The present study 
demonstrated for the first time a direct connection between O-glycosylation and Wnt 
signaling. In conclusion, these data provide a solid groundwork for further investigations in 
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